Document:

Exhibit

Exhibit 10.3

CERNER EXECUTIVE EMPLOYMENT AGREEMENT
This Cerner Executive Employment Agreement (this "Agreement"), effective as of February 1, 2018 (the "Effective Date"), describes the formal employment relationship between D. Brent Shafer ("you"/"your") and Cerner Corporation, a Delaware corporation ("Cerner").  
AGREEMENT
In consideration of the mutual covenants, promises, and obligations set forth herein, the parties agree as follows: 
		
	A.
	By accepting the offer of employment and executing this Agreement, you represent that every material fact contained in your resume and related documents that you supplied to Korn Ferry is true and accurate. Misrepresentation or omission of a material fact or falsification in such resume and related documents are grounds for immediate termination for Cause.

		
	B.
	Definitions of capitalized terms used but not otherwise defined herein can be found in Appendix A.

		
	1.
	EMPLOYMENT RELATIONSHIP.

		
	A.
	Type. To the extent permitted by law, your employment relationship with Cerner is "at will," which means that you may resign from Cerner at any time, for any reason or for no reason at all, and without advance notice (except as described below). It also means that Cerner may terminate your employment at any time - for any legally permitted reason or for no reason at all and without advance notice, subject to Cerner’s potential obligations to you under Paragraph 3 below.

		
	B.
	Compensation. You will be paid a base salary, specified use of Cerner's airplanes and you may receive a bonus, all as determined by Cerner's Board of Directors from time to time, and initially as set forth in Cerner's Offer Terms to you attached hereto as Appendix B. You will be entitled to receive the benefits generally provided to other Cerner Associates, and such other benefits as determined by Cerner's Board of Directors from time to time. In addition, Cerner shall reimburse you for your reasonable travel, meals, entertainment, and other similar expenses reasonably incurred in the performance of your duties, as long as such expenses are accompanied by valid receipts and any other documentation required pursuant to any applicable Cerner policy. The Cerner Board of Directors will have the ability to review the expenses presented, and any expenses that are reasonably rejected by the Board of Directors shall not be reimbursed by Cerner.

		
	C.
	Duties. You are being employed as Cerner's Chairman of the Board and Chief Executive Officer to perform the duties and responsibilities normally attendant with such positions and as assigned to you from time to time by Cerner's Board of Directors. You shall report directly to Cerner's Board of Directors. During your employment, you will devote your full time, attention and energies to the business of Cerner. Notwithstanding the foregoing, you are not precluded from engaging in other business activities outside normal business hours so long as such other business activities do not detract from your activities on behalf of Cerner and are in compliance with applicable Cerner policies, including without limitation Cerner’s Conflict of Interest Policy (as amended from time to time).

 
		
	2.
	RESIGNATION AND TERMINATION.

		
	A.
	Termination by Cerner. Cerner may terminate your employment (i) at any time with or without Cause, or (ii) upon your Disability. Your employment with Cerner shall be deemed automatically terminated upon your death. Upon a termination of your employment by Cerner for Cause, due to your death or on account of Disability (each an "Ineligible Severance Event"), Cerner shall pay you within thirty (30) days following your last day of employment (x) any accrued but unpaid base salary, (y) any owed reimbursements for unreimbursed business expenses properly incurred by you prior to your termination date, which shall be subject to and paid in accordance with Cerner's expense reimbursement policy; and (z) such employee benefits (including equity compensation or cash bonuses earned as of the termination date but not yet paid), if any, to which you may be entitled under Cerner's employee benefit 

plans as of your termination date; provided that, in no event shall you be entitled to any payments in the nature of any other severance or termination payments (such as under Cerner's Enhanced Severance Pay Plan). Those amounts described in this Paragraph 2.A (x), (y) and (z) are referred to herein collectively as the "Accrued Amounts." Payment upon termination of your employment by Cerner for any reason other than an Ineligible Severance Event is covered by Paragraph 3.
  
		
	B.
	Termination by You. You may resign from your employment with Cerner at any time upon written notice to Cerner of your intention to resign from employment. Any resignation notice must be submitted to Cerner at least thirty (30) days prior to your intended last day of employment. Cerner, however, reserves the right either to accelerate your last day of employment or to allow your intended last day of employment to stand. If you resign with fewer than thirty (30) days' notice, or if you actually leave Cerner's employ prior to expiration of the notice period without the permission of Cerner, then you agree that (to the extent permitted by law) no Accrued Amounts from the date you submitted your resignation notice to your last day of employment will be owed or paid to you by Cerner. All other Accrued Amounts will be paid. You may also terminate your employment hereunder upon written notice to Cerner in the event of a Constructive Termination (before a Change in Control) or for Good Reason (after a Change in Control) and, subject to you satisfying your obligations under Paragraph 3.C. (Severance Agreement and Release), be entitled to certain severance and benefit compensation as provided in Paragraph 3.

You agree to report to Cerner the identity of your new employer (if any) and the nature of your proposed duties for that employer.    
		
	3.
	SEVERANCE AND BENEFITS.

 
		
	A.
	Non-Change in Control - Termination by Cerner for other than an Ineligible Severance Event or Resignation following Constructive Termination. Subject to you satisfying your obligations under Paragraph 3.C. (Severance Agreement and Release), if, prior to a Change in Control or at any time after twelve (12) months following a Change in Control, (i) Cerner terminates your employment other than in connection with an Ineligible Severance Event or (ii) you resign from employment following a Constructive Termination, Cerner will within sixty (60) days (or later if required by Code Section 409A) of your termination of employment (unless such sixty (60) day period begins in one taxable year and ends in another taxable year, in which case the following payments will not be made until the beginning of the second taxable year):

		
	1.
	Pay you your Accrued Amounts; and

		
	2.
	Commence severance payments to you equal to the sum of (i) two (2) year's base salary, plus (ii) two (2) times the average annual cash bonus you received from Cerner during the three (3) years preceding the termination of your employment, less (iii) normal tax and payroll deductions. The severance payments contemplated by the immediately preceding clause (i) will be based on your annual base salary at the time of your termination; provided, however, that if you resign from employment following a Constructive Termination because of a material reduction in your total target compensation, such severance payments will be based on your annual base salary immediately prior to such reduction. Such severance pay will be payable pro rata during the twenty-four (24) month severance term on Cerner’s regular paydays; and 

		
	3.
	Commence payments to you having an aggregate value equal to twenty-four (24) times the difference between the monthly COBRA continuation premium cost to cover you and your dependents (to the extent covered under Cerner's health, vision and dental the plans on the date of your termination of employment) under Cerner's health, vision and dental plans in effect as of the date of your termination and the monthly amount you were paying for such coverage at the effective date of your termination. Such payments will be payable pro rata during the twenty-four (24) month severance term on Cerner’s regular paydays. Notwithstanding the foregoing, if Cerner making payments under this Paragraph 3.A.3 would violate the nondiscrimination rules applicable to non-grandfathered plans under the Affordable Care Act or result in the imposition of penalties under the Affordable Care Act, the parties agree to reform this Paragraph 3.A.3 in a manner as is necessary to comply with the Affordable Care Act; and

		
	4.
	With respect to outstanding equity awards:

		
	a.
	Fully vest all outstanding unvested stock options or stock appreciation rights granted by Cerner to you and still held by you and all other outstanding equity-based compensation awards that are not intended to qualify as performance-based compensation under Code Section 162(m)(4)(C); provided that, any delays in the settlement or payment of such awards that are set forth in the applicable award agreement and that are required under Code Section 409A ("Section 409A") shall remain in effect; and

		
	b.
	Cause all outstanding equity-based compensation awards that are intended to constitute performance-based compensation under Code Section 162(m)(4)(C) (excluding stock options and stock appreciation rights which will fully vest in accordance with Paragraph 3.A.4.a.) to remain outstanding and vest or be forfeited in accordance with the terms of the applicable award agreements, if the applicable performance goals are satisfied.

		
	B.
	Change in Control - Termination by Cerner for other than an Ineligible Severance Event or Resignation for Good Reason. Subject to you satisfying your obligations under Paragraph 3.C. (Severance Agreement and Release), if there is a Change in Control of Cerner and within twelve (12) months following the date such Change in Control becomes effective Cerner terminates your employment for any reason other than on account of an Ineligible Severance Event or you resign from employment with Good Reason, then Cerner will, within sixty (60) days (or later if required by Code Section 409A) of your termination of employment (unless such sixty (60) day period begins in one taxable year and ends in another taxable year, in which case the following payments will not be made until the beginning of the second taxable year):

		
	1.
	Pay you your Accrued Amounts;

		
	2.
	Pay you a lump sum severance payment equal to the sum of (i) two (2) years' base salary, plus (ii) two (2) times the average annual cash bonus you received from Cerner during the three (3) years preceding the termination or resignation of your employment, less (iii) normal tax and payroll deductions. The severance payments contemplated by the immediately preceding clause (i) will be based on your annual base salary at the time of your termination; provided, however, that if you resign from employment for Good Reason within twelve (12) months following the date a Change in Control of Cerner becomes effective because of a material reduction in your total target compensation, such severance payments will be based on your annual base salary immediately prior to such reduction;

		
	3.
	Commence payments to you having an aggregate value equal to twenty-four (24) times the difference between the monthly COBRA continuation premium cost to cover you and your dependents (to the extent covered under Cerner's health, vision and dental plans on the date of your termination of employment) under Cerner's health, vision and dental plans in effect as of the date of your termination and the monthly amount you were paying for such coverage at the effective date of your termination. Such payments will be payable pro rata during the twenty-four (24) month severance term on Cerner’s regular paydays. Notwithstanding the foregoing, if Cerner's making payments under this Paragraph 3.B.3 would violate the nondiscrimination rules applicable to non-grandfathered plans under the Affordable Care Act or result in the imposition of penalties under the Affordable Care Act, the parties agree to reform this Paragraph 3.B.3 in a manner as is necessary to comply with the Affordable Care Act; and

		
	4.
	Fully vest all outstanding unvested equity incentive awards granted to you under any Cerner equity incentive plans. For purposes of this Paragraph 3.B.4, any performance-based award shall become vested or settled assuming an "at-target" level of goal achievement had been attained.

		
	C.
	Severance Agreement and Release. As a condition to your receiving severance in accordance with this Paragraph 3, upon your resignation or the termination of your employment, you agree to promptly execute and not revoke a written severance agreement, which release will be provided to you within ten (10) days of your termination date, containing normal and customary provisions, including but not limited to, a release releasing Cerner from any claims against Cerner related to your employment with Cerner that you might have at the time of or following the termination of your employment, and reasonable and customary representations and warranties.

		
	D.
	Forfeiture and Reimbursement. Further, notwithstanding anything to the contrary in this Agreement, if you breach any confidentiality, non-competition or other material provision of this Agreement following the termination of your employment with Cerner, Cerner's obligation, if applicable, to deliver severance payments and benefits to you under this Paragraph 3, and the vesting of any equity incentive awards described in this Paragraph 3 or Paragraph 4, will cease immediately, you will reimburse Cerner the amount of severance payments delivered to you by Cerner prior to such breach by you, and you will forfeit to Cerner all equity incentive awards (or the proceeds of exercised awards) that vested based on or after such termination of your employment and prior to your breach.

		
	E.
	ERISA Claims Review Procedures. To the extent any severance payments described in this Paragraph 3 are covered by the Employee Retirement Income Security Act of 1974, as amended, Claims Review Procedures are available from Cerner.

		
	F.
	Compliance with Section 409A.

		
	1.
	General Compliance. This Agreement and any severance payments contemplated to be made hereunder is intended to comply with Section 409A or an exemption thereunder and shall be construed and administered in accordance with Section 409A. Notwithstanding any other provision of this Agreement, payments provided under this Agreement may only be made upon an event and in a manner that complies with Section 409A or an applicable exemption. Any payments under this Agreement that may be excluded from Section 409A either as separation pay due to an involuntary separation from service or as a short-term deferral shall be excluded from Section 409A to the maximum extent possible. For purposes of Section 409A, each installment payment provided under this Agreement shall be treated as a separate payment. Any payments to be made under this Agreement upon a termination of employment shall only be made upon a "separation from service" under Section 409A. Notwithstanding the foregoing, Cerner makes no representations that the payments and benefits provided under this Agreement comply with Section 409A, and in no event shall Cerner be liable for all or any portion of any taxes, penalties, interest, or other expenses that may be incurred by you on account of non-compliance with Section 409A.

		
	2.
	Specified Employees. Notwithstanding any other provision of this Agreement, if any payment or benefit provided to you in connection with your termination of employment is determined to constitute "nonqualified deferred compensation" within the meaning of Section 409A and you are determined to be a "specified employee" as defined in Section 409A(a)(2)(b)(i), then such payment or benefit shall not be paid until the first payroll date to occur following the six-month anniversary of the your termination date or, if earlier, on your death (the "Specified Employee Payment Date"). The aggregate of any payments that would otherwise have been paid before the Specified Employee Payment Date shall be paid to you in a lump sum on the Specified Employee Payment Date and thereafter, any remaining payments shall be paid without delay in accordance with their original schedule.

		
	3.
	Reimbursements. To the extent required by Section 409A, each reimbursement or in-kind benefit provided under this Agreement shall be provided in accordance with the following:

		
	a.
	the amount of expenses eligible for reimbursement, or in-kind benefits provided, during each calendar year cannot affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year;

		
	b.
	any reimbursement of an eligible expense shall be paid to you on or before the last day of the calendar year following the calendar year in which the expense was incurred; and

		
	c.
	any right to reimbursements or in-kind benefits under this Agreement shall not be subject to liquidation or exchange for another benefit.

		
	4.
	PARTIAL ACCELERATED VESTING UPON A CHANGE IN CONTROL.

In connection with a Change in Control, 50% of each outstanding and unvested equity incentive award granted to you under any Cerner equity incentive plan prior to the date the Change in Control becomes effective will become vested on the date the Change in Control becomes effective. The remaining 50% of each such outstanding equity incentive award that has not yet vested will continue to vest according to its vesting schedule, unless (i) within twelve (12) months following the date the Change in Control becomes effective (A) your employment is terminated for any reason other than in connection with an Ineligible Severance Event or (B) you resign for Good Reason, in which cases (A) or (B), 100% of such award will become vested as provided above in Paragraph 3.B); or (ii) if at any time after twelve (12) months following a Change in Control (A) your employment is terminated for any reason other than in connection with an Ineligible Severance Event or (B) the termination of your employment on account of a Constructive Termination, in which cases (A) or (B), 100% of such award will become vested as provided above in Paragraph 3.A). For purposes of this Paragraph 4, any performance-based award which becomes 50% vested upon a Change in Control shall mean that an "at-target" level of goal achievement had been attained with respect to 50% of the award.

		
	5.
	AGREEMENT NOT TO DISCLOSE OR TO USE CONFIDENTIAL INFORMATION.

You understand that the business of Cerner and the nature of your employment may require you to have access to Confidential Information of and about Cerner, Cerner solutions, and Clients and Suppliers. You agree that you will forever maintain the confidentiality of Confidential Information. You will never disclose Confidential Information except to persons who have both the right and need to know it, and then only for the purpose and in the course of performing Cerner duties and in accordance with Cerner policies. You will also never use Confidential Information, or remove from Cerner any records containing Confidential Information except for the sole purpose of conducting business on behalf of Cerner and in accordance with Cerner policies. If your employment with Cerner terminates (voluntarily or involuntarily), you will promptly deliver to Cerner all Confidential Information, including any Confidential Information on any laptop, computer, mobile phone, or other communication equipment used by you to conduct Cerner business.

You agree to abide by Cerner's internal security and privacy policies as well as all client security and privacy policies that are relevant to your position. As an associate of a health care information technology provider, you may have access to confidential patient information that may be protected by international, federal, state and/or local laws. You agree to maintain the confidentiality of all confidential patient information, including but not limited to health, medical, financial or personal information (in any form), and you agree not to use any confidential patient information in any manner other than as expressly permitted by all applicable rules and regulations.
You acknowledge, understand and agree that Confidential Information does not lose its status as Confidential Information merely because you commit it to, or create it from, memory.
You understand and agree that Cerner does not expect nor does it want you to disclose Trade Secrets or other confidential information of any of your former employers, and you acknowledge that it is your responsibility not to disclose to Cerner any information in the nature of a trade secret which would violate your legal obligation to others.  
Nothing in this Agreement will (i) prohibit you from using or disclosing Confidential Information in connection with reporting possible violations of law or regulation to any governmental agency or entity or attorney in accordance with any whistleblower protection provisions of applicable law or regulation including 18 U.S.C. § 1833 or (ii) require notification or prior approval by Cerner of any reporting described in clause (i). However, any disclosure must be made in accordance with the applicable law or regulation and in a manner that limits-to the furthest extent possible-disclosure of Confidential Information.

		
	6.
	WORK PRODUCT.

With respect to Work Product that you develop, author, conceive, or reduce to practice-in whole or in part while employed at Cerner-you agree to keep accurate, complete, and timely records of the Work Product and will promptly disclose and fully describe the Work Product in writing to Cerner. You agree to maintain all information respecting any Work Product as Confidential Information and will not disclose the information to any party outside of Cerner, except to persons who have both the right and need to know it and then only for the purpose and in the course of performing Cerner duties.
In consideration of your employment with Cerner, the potential severance payments and potential acceleration of the vesting of outstanding equity incentive awards described herein, and the potential benefits to you in the event of a Change in Control of Cerner (the sufficiency of such consideration you hereby acknowledge), you agree and hereby assign and transfer to Cerner, without further consideration, your entire right, title and interest in and to all Work Product. If for any reason any Work Product would not be considered a work made for hire under applicable law, you hereby assign and transfer to Cerner the entire right, title, and interest in and to the Work Product and all intellectual property rights in the Work Product. You hereby waive any and all moral rights and similar rights of copyright holders in other countries - including but not limited to rights of attribution and integrity or equivalent rights- which you would otherwise have in any Work Product.
You agree to execute promptly, at Cerner's expense, a written assignment of title to Cerner and all letters (and applications for letters) of patent, copyright, trademark or other intellectual property right, in all countries, for any Work Product required to be assigned by this Agreement. You also agree to assist Cerner or its nominee in every reasonable way (at Cerner's request and expense, but at no charge to Cerner), both during and after your time of employment at Cerner, in vesting and defending title to the Work Product in and for Cerner, in any and all countries, including the obtainment and preservation of patents, copyrights, Trade Secrets, trademarks, and other intellectual property rights.
This Paragraph does not apply to your solutions and ideas that are developed entirely on your own time and do not relate directly or indirectly to the business of Cerner or to Cerner's actual or demonstrably anticipated research or development.
		
	7.
	PRIOR INVENTIONS.

Any and all patented and unpatented inventions, new solutions, and ideas that you made prior to your employment by Cerner are excluded from the scope of this Agreement and are documented on Appendix C, Inventory of Prior Inventions.

		
	8.
	NON-COMPETITION, NON-SOLICITATION AND NON-DISPARAGEMENT.

In consideration of your employment with Cerner, the potential severance payments and potential acceleration of the vesting of outstanding equity incentive awards described herein, and the potential benefits to be provided to you in the event of a Change in Control of Cerner (the sufficiency of such consideration you hereby acknowledge), during the term of this Agreement and for a period of two (2) years after the voluntary or involuntary termination of your employment with Cerner (with or without Cause or Good Reason):
		
	A.
	You will tell any prospective new employer, prior to accepting employment that this Agreement exists.

		
	B.
	You will not, directly or indirectly for yourself or for any other person, entity or organization, provide services directly or indirectly of a type similar to those related to or involved with your employment at Cerner to any Conflicting Organization (i) in the United States, or (ii) in any country in which Cerner has a business interest. However, you may accept employment with a large Conflicting Organization whose business is diversified, but only with respect to the portion of such Conflicting Organization’s business that does not involve and is not related to a Conflicting Solution. But, prior to your acceptance of such employment, Cerner must receive separate written assurances satisfactory to Cerner from the Conflicting Organization and from you that you will not render services directly or indirectly in connection with any Conflicting Solution.

		
	C.
	Notwithstanding the foregoing, nothing contained in this Paragraph 8 shall prohibit you (after your termination of employment with Cerner) from taking a position with a general consulting organization 

if its only Conflicting Solution is the provision of consulting services to the health care industry, so long as you personally do not provide or assist in providing consulting services to a Client with respect to any Conflicting Solution.

		
	D.
	You agree not to, directly or indirectly on behalf of yourself or on behalf of any other person, entity or organization, employ, solicit for employment, or otherwise seek to employ or retain any Cerner Associate or any employee of a Cerner Client company or in any way assist or facilitate any such employment, solicitation or retention effort.

		
	E.
	You agree that both during your employment with Cerner and after termination of your employment with Cerner you will never make recklessly or maliciously false accusations or remarks in any form-including written, oral, or electronic form-for the purpose of disparaging Cerner’s solutions or services.

You have carefully read and considered the provisions of this Paragraph 8 and agree that (i) the restrictions set forth herein are fair and reasonable and are reasonably required for the protection of Cerner's interests, and (ii) your experience, capabilities and personal assets are such that the restrictive provisions of this Paragraph 8 would not deprive you from either earning a livelihood in the unrestricted business activities that remain open to you or from otherwise adequately supporting yourself and your family.
		
	9.
	PUBLICITY RELEASE.

You consent to the use of your name, voice and picture (including but not limited to use in still photographs, videotape and film formats, and both during and after your employment with Cerner) for advertising, promotional, public relations, and other business purposes (including use in web sites, online communication forums, newspapers, brochures, magazines, journals and films or videotapes) by Cerner and Cerner Clients.
		
	10.
	CERNER PROPERTY.

When physical Cerner Property is formally issued to you, you will acknowledge receipt of it when requested to do so and will take all reasonable precautions and actions necessary to safeguard and maintain it in normal operating condition. You further agree to accept financial responsibility for damage or wear to the Cerner Property you are issued beyond that associated with normal business use. You will notify Cerner immediately of any damage or loss. If your employment with Cerner terminates (for any reason), you will immediately return to Cerner all Cerner Property issued, delivered, accessed or which otherwise belongs to Cerner. You understand that Cerner's time off policy states that upon termination, for whatever reason, accrued time off will be paid out - if applicable or paid out at all - in accordance with the policy and subject to applicable state law, only after Cerner has received all Cerner Property issued to you or then in your possession. You agree to reimburse Cerner for any attorneys' fees and other collection charges incurred by Cerner in the event it becomes necessary to file a replevin or other legal action to recover the Cerner Property from you.
		
	11.
	CERNER POLICIES.

You agree that your employment is subject to the policies and procedures of Cerner as amended from time to time and that you will comply with and assist in the vigorous enforcement of all policies, practices, and procedures. You understand that a material violation of Cerner policies, practices, and procedures may result in termination of your employment for Cause.  
		
	12.
	NO RESTRICTIONS.

By accepting the offer of employment and executing this Agreement, you represent and warrant that to the best of your knowledge you are not subject to any noncompetition, non-solicitation or confidentiality agreements that your employment by Cerner, or contemplated work activities at Cerner, would violate. You also represent and agree that you will not disclose to Cerner, or induce Cerner to use, any proprietary, confidential or Trade Secret information belonging to any previous employer or other third parties. If it is determined that a valid and enforceable agreement exists that, in Cerner's sole discretion, would prevent or materially restrict your ability to perform your duties under this Agreement (a "Restrictive Agreement"), Cerner shall have the option to terminate this Agreement immediately and such termination shall be considered an Ineligible Severance Event. In the event that Cerner terminates this Agreement pursuant to the immediately preceding sentence, all other agreements entered into by and between you and Cerner (including any equity grants or bonus 

payments that have not yet vested or been paid, respectively) shall also terminate, and, notwithstanding Paragraph 14 below, neither party shall be liable to the other party hereto for any damages (including attorneys' fees), indemnification obligations, liability, actions, suits or other claims arising out of or relating to the existence of a Restrictive Agreement or the enforcement of any provisions or remedies thereunder.
		
	13.
	REMEDIES.

By signing this Agreement, you agree that the promises you have made in it are of a special nature, and that any breach, violation or evasion by you of the terms of this Agreement will result in immediate and irreparable harm to Cerner. It will also cause damage to Cerner in amounts difficult to ascertain. Accordingly, Cerner will be entitled to the remedies of injunction and specific performance, as well as to all other legal and equitable remedies that may be available to Cerner. You and Cerner hereby waive the posting of any bond or surety required prior to the issuance of an injunction hereunder. However, in the event that a court refuses to honor the waiver of bond, you and Cerner agree to a bond of $500. In addition, unless otherwise prohibited by law, you and Cerner waive the award of consequential and/or punitive damages in any action related to this Agreement or your employment with Cerner.
		
	14.
	INDEMNIFICATION.

You agree to indemnify, defend and hold Cerner harmless from and against any damages (including reasonable attorneys' fees), liability, actions, suits or other claims arising out of your breach of this Agreement. Cerner agrees to indemnify, defend and hold you harmless from and against any damages (including reasonable attorneys’ fees), liability, actions, suits or other claims arising out of Cerner’s breach of this Agreement.
		
	15.
	MODIFIED 280G CARVE-BACK.

  
Notwithstanding anything contained in this Agreement to the contrary, if on an after-tax basis the aggregate payments and benefits paid pursuant to Paragraph 3.B or Paragraph 4 would be larger if the portion of such payments and benefits constituting "parachute payments" under Code Section 280G were reduced by the minimum amount necessary to avoid the imposition of the excise tax under Code Section 4999, then such payments and benefits shall be reduced by the minimum amount necessary to avoid such excise tax. Any such reduction shall occur in a manner that maximizes your economic position. In applying this principle, the reduction shall be made in a manner consistent with the requirements of Section 409A, and where two economically equivalent amounts are subject to reduction but payable at different times, such amounts shall be reduced on a pro rata basis but not below zero. Any determination required under this Paragraph 15 shall be made in writing in good faith by an accounting firm selected by Cerner, which is reasonably acceptable to you (the "Accountants"). Cerner and you shall provide the Accountants with such information and documents as the Accountants may reasonably request in order to make a determination under this Paragraph 15. Cerner shall be responsible for all fees and expenses of the Accountants.
		
	16.
	MODIFICATION; NO WAIVER.

This Agreement may not be modified in any respect, except by a written agreement executed by you and an authorized representative of Cerner's Board of Directors. However, (a) Cerner may from time to time publish and adopt supplementary policies with respect to the subject matter of this Agreement, and you agree that such supplementary policies shall be binding upon you; and (b) Cerner may modify this Agreement from time to time without your consent if Cerner's legal counsel deems doing so to be advisable to comply with Section 409A of the Code and you agree that any such modifications shall be binding upon you. No waiver of the terms of this Agreement will be effective unless made in writing and signed by an authorized representative of Cerner's Board of Directors. No failure to exercise and no delay in exercising any right, remedy or power under this Agreement will operate as a waiver thereof. No single or partial exercise of any right, remedy or power under this Agreement will precluded any other or further exercise thereof or the exercise of any other right, remedy or power contained in this Agreement or by law or in equity.
		
	17.
	NOTICES.

Any notice required or permitted to be given pursuant to the terms of the Agreement shall be sufficient if given in writing and if personally delivered by receipted hand delivery to you or to Cerner, or if deposited in the United States mail, postage prepaid, first class or certified mail, to you at your residence address or to Cerner's 

corporate headquarters address or to such other addresses as each party may give the other party notice in accordance with this Agreement.
		
	18.
	SURVIVING PROVISIONS.

Notwithstanding the termination of the employment relationship underlying this Agreement, the rights and obligations set forth in this Agreement with respect to both parties will survive such termination as necessary to permit the intent of the provisions to be carried out.
		
	19.
	GOVERNING LAW; JURISDICTION AND LEGAL FEES.

This Agreement will be governed by, construed, interpreted, and its validity determined, under the laws of the State of Missouri, without regard to its conflict of law principles. Except for matters covered by the Cerner Mutual Arbitration Agreement (which is being entered into by you and Cerner contemporaneously and in conjunction with this Agreement as a condition to and in consideration of your employment by Cerner), you and Cerner each irrevocably and unconditionally submit to the exclusive jurisdiction of any Missouri state court or federal court of the United States of America sitting in Kansas City, Missouri, in any action or proceeding arising out of or relating to this Agreement. In any such action or proceeding, the non-prevailing party shall pay the reasonable attorneys’ fees and costs of the prevailing party.
		
	20.
	SEVERABILITY.

If any provision of this Agreement is held to be unenforceable, then this Agreement will be deemed amended to the extent necessary to render the otherwise unenforceable provision - and the rest of this Agreement -  valid and enforceable. In the event that any provisions of Paragraphs 5, 6, or 8 of this Agreement relating to time period and/or areas of restrictions shall be declared by a court of competent jurisdiction to exceed the maximum time period or areas such court deems reasonable and enforceable, said time period and/or areas of restriction shall be deemed to become and thereafter be the maximum time period and/or areas that such court deems reasonable and enforceable. If a court declines to amend this Agreement as provided in this Paragraph, the invalidity or unenforceability of any provision of this Agreement will not affect the validity or enforceability of the remaining provisions, which must be enforced as if the offending provision had not been included in this Agreement.
		
	21.
	ENTIRE AGREEMENT AND PRIOR AGREEMENTS AND NO WAIVER.

You hereby acknowledge receipt of a signed counterpart of this Agreement. You agree that this Agreement, together with the Cerner Mutual Arbitration Agreement (which is being entered into by you and Cerner contemporaneously and in conjunction with this Agreement as a condition to and in consideration of your employment by Cerner), is your entire agreement with Cerner concerning the subject matter hereof, and this Agreement cancels, terminates and supersedes any of your previous oral or written understandings or agreements with Cerner or with any director, officer or representative of Cerner with respect to your employment with Cerner (other than said Cerner Mutual Arbitration Agreement). Without limitation, the severance benefits and payments eligible to be provided under this Agreement supersede and replace any benefits or payments you might otherwise be eligible to receive under the Cerner Enhanced Severance Pay Plan, any successor thereto, or any other broad-based Cerner severance plan or policy which otherwise would be applicable to you. The terms of this Agreement may not be modified except in a writing signed by an authorized representative of Cerner’s Board of Directors and you. No waiver of the terms of this Agreement will be effective unless made in writing and signed by an authorized representative of Cerner’s Board of Directors. No failure to exercise and no delay in exercising any right, remedy or power under this Agreement will operate as a waiver thereof. No single or partial exercise of any right, remedy or power under this Agreement will preclude any other or further exercise thereof or the exercise of any other right, remedy or power under this Agreement or by law or equity. You agree that you are bound by the terms of the Cerner Mutual Arbitration Agreement except that, in addition to the claims identified in the Cerner Mutual Arbitration Agreement as "Claims Not Covered by this Agreement," the parties agree that any claims for indemnification by you arising out of the Indemnification Agreement (which is being entered into by you and Cerner contemporaneously and in conjunction with this Agreement as a condition to and in consideration of your employment by Cerner) or under Cerner's Third Amended and Restated Certificate of Incorporation or Amended and Restated Bylaws shall not be subject to the Cerner Mutual Arbitration Agreement.

		
	22.
	ASSIGNMENT AND SUCCESSORS.

Cerner may assign this Agreement to any of its subsidiaries, affiliates, parent companies, other related entities or to the acquiring entity in a Change of Control transaction without written notice or your prior consent. This Agreement shall be binding upon Cerner’s successors and assigns. You agree that, should Cerner be acquired by, merge with, or otherwise combine with another corporation or business entity, the surviving entity will have all rights to enforce the terms of this Agreement as if it were Cerner itself enforcing the Agreement. This Agreement shall also be binding upon your heirs, spouse, assigns and legal representatives. You, however, agree that you may not delegate the performance of any of your obligations or duties hereunder, or assign any rights hereunder, without the prior written consent of Cerner. Any such reported delegation or assignment in the absence of any such written consent shall be void.  
This Agreement is executed as of this 10th day of January 2018.
	
					
	 
	 
	 
	 
	 

	 
	/s/ D. Brent Shafer
	 
	 

	 
	D. Brent Shafer
	 
	 

	 
	 
	 
	 
	 

	 
	Cerner Corporation
	 
	 

	 
	 
	 
	 
	 

	 
	By:
	/s/ Julia M. Wilson
	 
	 

	 
	 
	Julia M. Wilson
	 
	 

	 
	 
	Executive Vice President and Chief People Officer

APPENDIX A
DEFINITION OF TERMS
ASSOCIATE means a Cerner employee.
CAUSE means your material breach of this Agreement, fraud against Cerner, misappropriation of Cerner’s assets, willful dishonesty that is injurious to Cerner, embezzlement from Cerner, theft from Cerner, material neglect of your duties and responsibilities hereunder, your arrest and indictment for a crime involving drug abuse, violence, dishonesty or theft, your taking any action or omitting to take any action that results in a violation of the Sarbanes-Oxley Act of 2002, or any related statutes, laws or regulations or material breach of Cerner’s policies, practices and procedures.
CERNER CORPORATION and CERNER mean Cerner Corporation, a Delaware corporation. Where applicable the terms may also cover all of Cerner Corporation's parent, subsidiary and affiliate corporations and business enterprises, both presently existing and subsequently created or acquired. Subsidiary and affiliate corporations may be directly or indirectly controlled by Cerner or related to Cerner by equity ownership.
CERNER PROPERTY means the various items of Cerner property and equipment assigned to you to help you carry out your Cerner responsibilities, including but not limited to keys, credit cards, access cards, parking passes, Cerner Confidential Information, laptops, computer related and other office equipment, mobile telephone, pagers and/or other computer or communication devices.
CHANGE IN CONTROL means:
		
	(i)
	The acquisition by any individual, entity or group (a "Person") within the meaning of Section 12(d)(3) or 13(d)(2) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 35% or more of either:  (A) the then outstanding shares of common stock of Cerner (the "Outstanding Cerner Common Stock"), or (B) the combined voting power of the then outstanding voting securities of Cerner entitled to vote generally in the election of directors (the "Outstanding Cerner Voting Securities"); provided, however, that for purposes of this subsection (i), the following acquisitions shall not constitute a Change in Control:  (X) any acquisition directly from Cerner, (Y) any acquisition by Cerner, or (Z) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by Cerner or any corporation controlled by Cerner; or

		
	(ii)
	Individuals who, as of the date hereof, constitute Cerner’s Board of Directors (the "Incumbent Board") cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to the date hereof whose election, or nomination for election by Cerner's shareholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board; or

		
	(iii)
	Consummation of a reorganization, merger or consolidation or sale or other disposition of all or substantially all of the assets of Cerner (a "Business Combination"), in each case, unless, following such Business Combination, (A), all or substantially all of the individuals and entities who were the beneficial owners, respectively, of the Outstanding Cerner Common Stock and Outstanding Cerner Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of, respectively, the then outstanding shares of common stock and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of Cerner resulting from such Business Combination (including, without limitation, a corporation which as a result of such transaction owns Cerner or all or substantially all of Cerner’s assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership, immediately prior to such Business Combination of the Outstanding Cerner Common Stock and Outstanding Cerner Voting Securities, as the case may be, (B) no Person (excluding any employee benefit plan (or related trust) of Cerner or such corporation resulting from such Business Combination) beneficially owns, directly or indirectly, 35% or more of, respectively, the then outstanding shares of common stock of Cerner resulting from such Business Combination or the combined voting power of the then outstanding voting securities of such corporation except to the extent that such 

ownership existed prior to the Business Combination, and (C) at least a majority of the members of the Board of Directors of Cerner resulting from such Business Combination were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the board, providing for such Business Combination; or
		
	(iv)
	Approval by the shareholders of Cerner of a complete liquidation or dissolution of Cerner.

CLIENT means any actual or potential customer or licensee of Cerner.
CODE means the Internal Revenue Code of 1986, as from time to time amended.
CONFIDENTIAL INFORMATION means Cerner, Client and Supplier Trade Secrets and proprietary information, Cerner, Cerner Associate, Client and Supplier information which is not generally known, and is proprietary or confidential to Cerner, Cerner Associates, Clients or Suppliers. It includes, but is not limited to, research, design, development, installation, purchasing, accounting, marketing, selling, servicing, finance, business systems, business practices, documentation, methodology, procedures, manuals (both internal and user), program listings, computer software in source code, object or other form, working papers, Client and Supplier lists, marketing and sales materials not otherwise available to the general public, sales activity information, computer programs and software, compensation plans, your personal compensation or performance evaluations (specifically, no Associate may disclose Cerner compensation structures or bonus programs with Conflicting Organizations, in addition, Associates in supervisory or managerial roles may not disclose their personal compensation or their performance evaluations with anyone other than their manager or with Cerner Human Resources), patient information and other client-related data, and all other non-public information of Cerner and its Associates, Clients and Suppliers. CONFIDENTIAL INFORMATION will not include any information that has been voluntarily disclosed to the public by Cerner (except where such public disclosure has been made by you without authorization) or that has been independently developed and disclosed without confidentiality protections by others, or that otherwise enters the public domain through lawful means. Notwithstanding the foregoing, you may disclose your personal compensation, performance evaluations or other information concerning your employment with Cerner to your attorneys, accountants, tax advisors or the Internal Revenue Service.
CONFLICTING ORGANIZATION means any person or organization engaged (or about to become engaged) in research, development, installation, marketing, selling or servicing with respect to a Conflicting Solution.
CONFLICTING SOLUTION means any solution, product, process or service which is the same as, similar to, or competes with any Cerner solution, product, process or service with which you worked or supervised, directly or indirectly, during the last three (3) years of your employment by Cerner, or about which you have acquired Confidential Information or which you developed, authored or conceived, in whole or in part, at any time during your employment by Cerner.
CONSTRUCTIVE TERMINATION means the occurrence of any of the following without your consent: (1) a material, adverse change in your authority, position, duties, or responsibilities (other than temporarily while you are physically or mentally incapacitated or as required by applicable law) or reporting structure such that you no longer report to Cerner's Board of Directors, (2) a material reduction in your total target compensation (which equals the sum of your annual base salary, target annual bonus and ongoing annual equity grant), excluding any reduction related to a broader compensation reduction or redesign by Cerner that is not limited to you, (3) a relocation of the principal location at which you are required to perform your duties to more than twenty-five (25) miles from the Kansas City metropolitan area and which is adverse to you, or (4) any other action or inaction that constitutes a material breach by Cerner of this Agreement. You cannot terminate your employment on account of a Constructive Termination unless you have provided written notice to Cerner of the existence of the circumstances providing grounds for termination on account of a Constructive Termination within thirty (30) days of the initial existence of such grounds and Cerner has had at least thirty (30) days from the date on which such notice is provided to cure such circumstances. If you do not terminate your employment on account of a Constructive Termination within ninety (90) days after the first occurrence of the applicable grounds, then you will be deemed to have waived your right to terminate on account of a Constructive Termination with respect to such grounds.
DISABILITY means a physical or mental illness, as determined by an accredited physician, which causes you to be unable to perform your duties hereunder for ninety (90) consecutive days, or for an aggregate of ninety (90) days during any period of twelve (12) consecutive months.

GOOD REASON means the occurrence of any of the following, without your consent: (1) a material, adverse change in your authority, duties, position or responsibilities (other than temporarily while you are physically or mentally incapacitated or as required by applicable law) or reporting structure such that you no longer report to Cerner’s Board of Directors, (2) a material reduction in your total target compensation (which equals the sum of your annual base salary, target annual bonus and ongoing annual equity grant), excluding any reduction related to a broader compensation reduction or redesign by Cerner that is not limited to you, (3) a relocation of the principal location at which you are required to perform your duties to more than twenty-five (25) miles from the Kansas City metropolitan area and which is adverse to you, or (4) any other action or inaction that constitutes a material breach by Cerner of this Agreement. You cannot terminate your employment on account of a Good Reason unless you have provided written notice to Cerner of the existence of the circumstances providing grounds for termination on account of a Good Reason within thirty (30) days of the initial existence of such grounds and Cerner has had at least thirty (30) days from the date on which such notice is provided to cure such circumstances. If you do not terminate your employment on account of a Good Reason within ninety (90) days after the first occurrence of the applicable grounds, then you will be deemed to have waived your right to terminate on account of a Good Reason with respect to such grounds.
SUPPLIER means any actual or potential licensor, vendor, supplier, contractor, agent, consultant or other purveyor of solutions, products, processes or services.
TRADE SECRET means information, including but not limited to, technical or nontechnical data, a formula, pattern, compilation, program, device, method, technique, or process, that: (a) derives independent economic value, actual or potential, from not being generally known to, and not being readily ascertainable by proper means by other persons who can obtain economic value from its disclosure or use; and (b) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy.
WORK PRODUCT means discoveries, inventions, computer programs, improvements, data, works of authorship, designs, methods, ideas, solutions and other work product (whether or not they are described in writing, reduced to practice, patentable or copyrightable) which results from any work performed by you for Cerner, or involve the use of any Cerner equipment, supplies, facilities or Confidential Information, or relate directly to the business of Cerner, or relate to Cerner's actual or demonstrably anticipated research or development.

APPENDIX B

OFFER TERMS

	
			
	Name:
	D. Brent Shafer
	 

	 
	 
	 

	Position:
	Chief Executive Officer and Chairman of the Board
	 

	 
	Full-time, Salaried-Exempt
	 

CASH COMPENSATION

	
			
	Annual Base Salary:
	$800,000 annually
	 

	 
	 
	 

	Cerner Performance Plan:
	$1,200,000 annual target bonus level.
	 

The Cerner Performance Plan (CPP) provides additional, performance-based compensation opportunities tied to the attainment of group and/or individual performance goals. The specifics of your plan and metrics will be defined and approved by the Compensation Committee of the Cerner Board of Directors annually. You are eligible to participate in the plan immediately upon employment.

EQUITY

You will receive an initial stock option grant valued at $4,000,000. The number of options for Cerner common stock to be granted will be calculated using the Black-Scholes value of such stock options on the date of grant.

The options will be granted to you effective upon your employment. Cerner has a non-qualified stock option plan. The exercise price for any grant is set at the fair market value of Cerner stock at the time of such grant. The options vest over a period of five years (40% after two years, and 20% each year thereafter) and expire after ten years.

Subsequent annual equity grants will be made in conjunction with the executive annual performance and compensation cycle during the first quarter of each year (commencing in 2019). You will be subject to Cerner's stock ownership guidelines that apply to executives, officers, and members of the Board of Directors.

ONE-TIME EQUITY GRANT

You will receive a one-time grant of Cerner restricted stock units upon your commencement of employment valued at $3,700,000 to replace the potential equity value you might have earned if you remained with your current employer. This restricted share grant will be time-based, vesting ratably in equal amounts on March 1, 2018, 2020 and 2021.

PERSONAL USE OF CORPORATE AIRCRAFT

You will have access to Cerner's corporate aircraft for personal use with a value not to exceed $100,000 annually.  This benefit and allowance must be reviewed and approved by the Compensation Committee on an annual basis.

RELOCATION ASSISTANCE

Cerner will provide relocation assistance for your upcoming move to Kansas City in accordance with Cerner’s Platinum Relocation Guideline. Your relocation benefits include the following:

		
	•
	Shipment of personal goods and final move trip

		
	•
	Reimbursement for commissions on a home sale and/or home purchase, and/or expenses incurred in connection with breaking a lease, as applicable

		
	•
	Temporary accommodations

		
	•
	Other relocation allowances as appropriate

BENEFITS

Cerner offers a comprehensive set of benefits to address your physical, financial, and emotional health. At Cerner, we believe the foundation for a successful career starts with a variety of options that meet your needs while supporting a healthy lifestyle. A benefits overview will be provided in a separate communication.

Cerner Executives do not accrue paid time off and instead are encouraged to take time off on an as-needed basis while meeting business accountabilities and responsibilities.

CONDITIONS

This term sheet summarizes the offer for the position of Chief Executive Officer and Chairman of the Board of Cerner Corporation. However, this term sheet is not intended to constitute a complete statement of the terms and conditions of such offer and position or constitute a legally binding agreement between the parties. The specific terms and conditions governing your employment will be set forth in Cerner's Executive Employment Agreement, Cerner's Mutual Arbitration Agreement and the equity grant instruments. This offer of employment is further contingent upon the following:

		
	1.
	Successful completion of a background check.

		
	2.
	Successful completion of a drug screen.

		
	3.
	Acceptance of Cerner’s Executive Employment Agreement (attached).

		
	4.
	Acceptance of Cerner’s Mutual Arbitration Agreement (attached).

		
	5.
	Your agreement to relocate to Kansas City.

APPENDIX C

PRIOR INVENTION INVENTORY

None.Exhibit 10.1

 

CONTRIBUTION AGREEMENT

 

Dated as of January 1, 2018

 

by and among

 

Boston Therapeutics, Inc.,

a Delaware corporation

 

and

 

CureDM Group Holdings, LLC,

a Delaware limited liability company
and

the Members of CureDM Group Holdings,
LLC

 

     

     

    

 

CONTRIBUTION AGREEMENT

 

This Contribution Agreement
(“Agreement”), dated as of 12:00 a.m. January 1, 2018 (the “Closing Date”),
is by and among Boston Therapeutics, Inc. (“BTHE”), a corporation organized under the laws of the State
of Delaware, having an office for the transaction of business at 354 Merrimack Street, #4, Lawrence, Massachusetts 01843 and CureDM
Group Holdings, LLC (“CureDM”), a limited liability company organized under the laws of the State of
Delaware, having an office for the transaction of business at 5901 Indian School Road, Albuquerque, New Mexico 87110, and the members
of CureDM as listed on the signature pages and Schedule A hereto, constituting all of the members of CureDM (collectively,
the “CureDM Members”, and each individually, a “CureDM Member”), each having
an address as set forth on the signature pages hereto.

 

W I T N E S S E T H

 

WHEREAS, the
CureDM Members own the number of membership interests of CureDM set forth opposite their respective names on Schedule A,
which collectively represent one hundred percent (100%) of the issued and outstanding membership interests of CureDM (collectively,
the “CureDM Membership Interests”, and each individually, a “CureDM Membership Interest”).

 

WHEREAS, the
CureDM Members desire to contribute the CureDM Membership Interests to BTHE upon the terms and subject to the conditions of this
Agreement in exchange for an aggregate of 47,741,140 shares of newly issued shares of BTHE Common Stock, $0.001 par value per share,
of which 25,000,000 BTHE Shares shall be delivered on the Closing Date (the “Closing BTHE Shares”) and
22,741,140 BTHE Shares (the “Milestone BTHE Shares”) shall be delivered in four equal tranches of 5,685,285
BTHE Shares each upon the achievement of each milestone described herein, pursuant to the terms and conditions set forth in this
Agreement (the Closing BTHE Shares and the Milestone BTHE Shares are referred to herein collectively as the “BTHE Shares”),
which such issuance of the BTHE Shares will be exempt from the registration requirements of the Securities Act of 1933, as amended
(the “Securities Act”), pursuant to an exemption provided by Rule 506 promulgated under Regulation D
of the Securities Act, and Section 4(a)(2) of the Securities Act.

 

NOW THEREFORE,
on the stated premises and for and in consideration of the foregoing recitals, which are hereby incorporated by reference, the
mutual covenants and agreements hereinafter set forth and the mutual benefits to the parties to be derived herefrom and for other
good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, the parties hereto agree as follows:

 

SECTION 1

 

CONTRIBUTION

 

1.1           Contribution.
Upon the terms and subject to the conditions contained herein, on the Closing Date, the CureDM Members will contribute, transfer,
assign and deliver to BTHE their respective CureDM Membership Interests, such that following the contribution thereof, BTHE shall
own one hundred percent (100%) of the issued and outstanding CureDM Membership Interests. All contributions shall be free and clear
of all liens, claims or rights or offset of any kind.

 

     

     

    

 

1.2           Closing
BTHE Share Issuance. In consideration of each CureDM Member’s contribution of his, her or its respective CureDM Membership
Interest to BTHE, BTHE shall issue the Closing BTHE Shares to each of the CureDM Members in accordance with Schedule B,
on the Closing Date. All certificates evidencing such BTHE Shares shall be distributed to the CureDM Members within ten (10) days
of the Closing Date.

 

1.3           Milestone
BTHE Share Issuance. In consideration of each CureDM Member’s contribution of his, her or its respective CureDM Membership
Interest to BTHE, upon achievement of the milestones set forth below (each, a “Milestone” and collectively,
the “Milestones”), BTHE shall issue the Milestone BTHE Shares to each of the CureDM Members in accordance
with Schedule B, which such Milestone BTHE Shares shall be issued on the date of the achievement of each milestone
(each, a “Milestone Achievement Date”). All certificates evidencing such Milestone BTHE Shares shall
be distributed to the CureDM Members within five (5) days of the applicable Milestone Achievement Date.

 

(a)           Milestones.

 

(i)         Milestone
1—Execution of a manufacturing agreement with a contract manufacturing organization (“CMO”) for the clinical
supply of active pharmaceutical ingredient and transfer to the CMO of methods and specifications required for new clinical batch
production subject to BTHE having raised sufficient capital (of at least $750,000) to support the terms and conditions, including
payment criteria of such agreement with the CMO.

 

(ii)        Milestone
2—Completion of Phase 1b clinical study of HIP2B in type 1 diabetes patients and issuance of final report prior to December
31, 2019.

 

(iii)       Milestone
3—First patient enrolled in Phase 2 of HIP2B in type 1 diabetes patients.

 

(iv)       Milestone
4—The earlier of (1) submission of Phase 2 reports to FDA and receipt of approval to begin Phase 3 study enrollment pertaining
to HIP2B or (2) entry into a strategic agreement (license, collaboration, etc.) with respect to the Phase 3 development of of HIP2B.

 

(b)           Additional
Obligations of BTHE. BTHE will provide status updates regarding the Milestones as reasonably requested by any CureDM, Inc.,
which shall be no more than once per quarter. BTHE will provide prompt written notice of the achievement of each Milestone to the
CureDM Members.

 

(c)           Certification.
BTHE will provide the CureDM Members with written certification within thirty (30) days of each Milestone Achievement Date.

 

    2 

     

    

 

1.4           Closing.
The closing of the transactions contemplated hereby shall take place upon the execution and delivery of this Agreement by the parties
on the date hereof.

 

1.5           Closing
Events. On the Closing Date, each of the respective parties hereto shall execute, acknowledge, and deliver (or shall cause
to be executed, acknowledged, and delivered) any and all stock certificates, officers’ certificates, financial statements,
schedules, agreements, resolutions, rulings, or other instruments required by this Agreement to be so delivered on the Closing
Date, as provided in Section 8, together with such other items as may be reasonably requested by the parties hereto and their respective
legal counsel in order to effectuate or evidence the transactions contemplated hereby. Upon the execution and delivery of this
Agreement on the Closing Date, the ownership of the CureDM Membership Interests set forth on Schedule A shall transfer
to BTHE without any further action by the CureDM Members, and the Closing BTHE Shares shall be issued in the names and denominations
set forth on Schedule B hereto.

 

1.6           Compliance
with Applicable Securities Laws. Each of the CureDM Members agrees that he, she or it is
acquiring the BTHE Shares for investment purposes and will not offer, sell or otherwise transfer, pledge or hypothecate any of
the BTHE Shares issued to him, her or it (other than pursuant to an effective Registration Statement under the Securities Act)
directly or indirectly unless:

 

(a)       the
sale is to BTHE;

 

(b)       the
sale is made pursuant to an exemption or exclusion from registration under the Securities Act, provided by Rule 144, Rule
144A, or other rules or regulations promulgated thereunder; or

 

(c)       the
sale is made in any other transaction that does not require registration under the Securities Act or any applicable United States
state laws and regulations governing the offer and sale of securities, and the CureDM Member has furnished to BTHE an opinion of
counsel to that effect or such other written opinion as may be reasonably required by BTHE. 

 

The
CureDM Members acknowledge that the certificates representing the BTHE Shares shall bear the following legend:

 

THESE SECURITIES HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THESE SECURITIES MAY NOT BE SOLD, OFFERED FOR
SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT WITH RESPECT TO THE
SECURITIES UNDER THE ACT, EXCEPT IN A TRANSACTION PURSUANT TO RULE 144, RULE 144A OR A REGULATION OF THE ACT, OR ANY OTHER EXEMPTION
OR EXCLUSION FROM THE REGISTRATION REQUIREMENTS OF THE ACT (AND BASED UPON AN OPINION OF COUNSEL IF THE ISSUER REASONABLY SO REQUESTS).

 

    3 

     

    

 

SECTION 2

REPRESENTATIONS AND WARRANTIES OF CUREDM

 

CureDM, and CureDM,
Inc. and Loraine V. Upham in their capacities as CureDM Members, hereby represent and warrants to BTHE that, except as set forth
in the correspondingly numbered section of the disclosure schedule attached hereto (the “CureDM Disclosure Schedule”),
the statements contained in this Section 2 are true and correct in all material respects as of the Closing Date. The CureDM Disclosure
Schedule shall be arranged in sections corresponding to the sections contained in this Section 2. For purposes of this Section
2, the phrase “to the knowledge of CureDM” or any phrase of similar import shall be deemed to refer to the actual or
constructive knowledge of Loraine V. Upham and H. Joseph Reiser, PhD after due inquiry.

 

2.1           Organization
and Good Standing. CureDM is a limited liability company duly organized, validly existing and in good standing under the
laws of the State of Delaware, and is entitled to carry on its business as and in the places where such business is now conducted.
CureDM is qualified to do business as a foreign corporation in each jurisdiction, if any, in which the failure to be so qualified
would have a Material Adverse Effect on CureDM (as defined in Section 2.2(d) below). CureDM does not have any subsidiaries. CureDM
has not conducted any business under or otherwise used, for any purpose or in any jurisdiction, any fictitious name, assumed name,
trade name or other name, other than the name “CureDM”. Schedule 2.1 sets forth (a) the names of the
members of the board of directors of CureDM (the “Board of Directors of CureDM” and (b) the names of
the members of each committee of the Board of Directors of CureDM. CureDM has provided to BTHE true, correct and complete copies
of: (i) the certificate of formation and the Amended and Restated Limited Liability Operating Agreement of CureDM dated March 19,
2010 each as in effect on the date of this Agreement, and such copies reflect all amendments made thereto at any time prior to
the date of this Agreement (the “CureDM Organizational Documents”), (ii) the register of members of CureDM,
and (iii) the minutes and other records of the meetings and other proceedings (including any actions taken by written consent or
otherwise without a meeting) of the CureDM Members, the Board of Directors of CureDM and all committees of the Board of Directors
of CureDM (the documents referred to in clauses (i), (ii) and (iii), collectively, the “CureDM Constitutional Documents”).
There have been no formal meetings or other proceedings of the members of CureDM, the Board of Directors of CureDM or any committee
of the Board of Directors of CureDM that are not reflected in the CureDM Constitutional Documents. There has not been any material
violation of the CureDM Constitutional Documents, and CureDM has not taken any action that is inconsistent with the CureDM Constitutional
Documents. CureDM is not in any material default under or in violation of any provision of its Organizational Documents. The books
and records of CureDM are up to date, true, correct and complete in all material respects. To CureDM’s knowledge, all the
records of CureDM have been maintained materially in accordance with applicable laws and are in the actual possession and direct
control of CureDM and no written notice that any of them is materially incorrect has been received by CureDM.

 

    4 

     

    

 

2.2           Authorization;
Enforceability; No Breach. CureDM has all necessary limited liability company power and authority to execute this Agreement
and perform its obligations hereunder. This Agreement constitutes the valid and binding obligation of CureDM enforceable against
it in accordance with its terms, except as may be limited by bankruptcy, moratorium, insolvency or other similar laws generally
affecting the enforcement of creditors’ rights. The execution, delivery and performance of this Agreement by CureDM and the
consummation of the transactions contemplated hereby will not:

 

(a)       violate
any material provision of the CureDM Organizational Documents;

 

(b)       violate,
conflict with or result in the material breach of any of the terms of, result in a material modification of, otherwise give any
other contracting party the right to terminate, or constitute (or with notice or lapse of time or both constitute) a default under,
any material contract or other agreement to which CureDM is a party or by or to which it or any of its assets or properties may
be bound or subject;

 

(c)       violate
any order, judgment, injunction, award or decree of any court, arbitrator or governmental or regulatory body against, or binding
upon, CureDM or upon the properties or business of CureDM; or

 

(d)       to
CureDM’s knowledge, violate any statute, law or regulation of any jurisdiction applicable to the transactions contemplated
herein, which would have a Material Adverse Effect on CureDM. “Material Adverse Effect on CureDM” shall
mean any effect or change that would be materially adverse to the business, assets, condition (financial or otherwise), operating
results or operations of CureDM as they exist on the Closing Date, or on the ability of CureDM to consummate timely the transactions
contemplated hereby, as the context requires.

 

2.3           Compliance
with Laws. CureDM, to its knowledge, has complied with all federal, state, county and local laws, ordinances, regulations,
inspections, orders, judgments, injunctions, awards or decrees applicable to it or its business except for such non-compliance
that would not have a Material Adverse Effect on CureDM.

 

2.4           Litigation;
Actions and Proceedings. There is no outstanding order, judgment, injunction, award or decree of any court, governmental
or regulatory body or arbitration tribunal against or involving CureDM. There is no action, suit, investigation or proceeding pending
or, to CureDM’s knowledge, threatened, at law or in equity, before any arbitrator, court or other governmental authority,
nor any judgment, decree, injunction, award or order outstanding, against CureDM or its properties or rights that would reasonably
be expected to have a Material Adverse Effect on CureDM or that could reasonably be expected to have a Material Adverse Effect
on the consummation on any of the transactions contemplated by this Agreement.

 

2.5           Brokers
or Finders. No broker’s or finder’s fee will be payable by CureDM or a CureDM Member in connection with the
transactions herein contemplated, nor will any such fee be incurred as a result of any actions by CureDM.

 

    5 

     

    

 

2.6       Assets.
CureDM owns all rights, title and interest in and to its assets, free and clear of all liens, pledges, mortgages, security interests,
conditional sales contracts or any other encumbrances.

 

		2.7	Intellectual Property; Privacy.

 

(a)       To
the knowledge of CureDM, CureDM owns all of the Intellectual Property (as that term is defined below) used in, or necessary for,
the operation of the business as conducted as of the date hereof (collectively, the “CureDM Intellectual Property”),
free and clear of any encumbrance. Schedule 2.7 sets forth a list of all registered
Intellectual Property owned by CureDM. To the knowledge of CureDM, the use of the CureDM Intellectual Property in the conduct of
CureDM’s business or operations as currently conducted has not and does not materially infringe, violate or misappropriate
any Intellectual Property of any third party. There is no claim or litigation pending or, to the knowledge of CureDM, threatened
against CureDM alleging that the use of the CureDM Intellectual Property in the conduct of CureDM’s business or operations
as currently conducted infringes, violates or misappropriates any Intellectual Property of any third party or otherwise challenging
the use, ownership, licensing, validity or enforceability of any CureDM Intellectual Property owned (or purported to be owned)
by CureDM. For purposes of this Agreement, “Intellectual Property”
means any and all intellectual property rights, including all (i) patents, patent applications, patent disclosures and inventions,
(ii) trademarks, service marks, trade dress, trade names, logos and corporate names and registrations and applications for registration
thereof together with all of the goodwill associated therewith, (iii) Internet domain names, URLs and websites, (iv) copyrights
(registered or unregistered) and copyrightable works and registrations and applications for registration thereof, (v) mask works
and registrations and applications for registration thereof, (vi) software, (vii) trade secrets and other confidential information
(including ideas, formulas, compositions, inventions (whether patentable or unpatentable and whether or not reduced to practice),
know how, manufacturing and production processes and techniques, research and development information, drawings, algorithms, architectures,
layouts, product specifications, designs, plans, proposals, technical data, financial and marketing plans), and (viii) copies and
tangible embodiments thereof (in whatever form or medium).

 

(b)       All
employees, consultants and other persons who materially contributed to the conception, creation or development of any of the CureDM
Intellectual Property owned (or purported to be owned) by CureDM have assigned their Intellectual Property Rights to CureDM. CureDM
has taken all commercially reasonable efforts to maintain the confidentiality of all material trade secrets of CureDM.

 

(c)       CureDM
is in material compliance with all applicable laws relating to privacy, data protection, anti-spam, personally identifiable information,
and similar consumer protection laws (collectively, “Privacy Laws”). CureDM has taken all commercially
reasonable measures necessary or appropriate to protect and maintain the confidentiality of all personally identifiable information
and other confidential customer information collected by CureDM, if any, and to maintain the security of its data storage practices,
in each case, in accordance with all applicable Privacy Laws. CureDM has not received written notice of any claims or been charged
with any violation of any Privacy Laws or any failure to adequately protect or maintain the confidentiality of any personally identifiable
information and other confidential customer information. CureDM is not aware of any data breaches involving any personally identifiable
information collected by CureDM.

 

    6 

     

    

 

2.8           Capitalization.
The issued and outstanding membership interests of CureDM are owned of record and beneficially by the CureDM Members and in the
amounts reflected in Schedule A. CureDM has not granted, issued or agreed to grant, issue or make available any warrants,
options, subscription rights or any other commitments of any character relating to the securities of CureDM. All of the outstanding
CureDM Membership Interests are duly authorized and validly issued, fully paid and non-assessable. Other than the CureDM Organizational
Documents, CureDM is not a party to or bound by any, and to the knowledge of CureDM there
are no, agreements or understandings with respect to the voting (including pooling agreements, voting trusts and proxies) or sale
or transfer (including agreements imposing transfer restrictions) of any equity interests of CureDM. CureDM has never repurchased,
redeemed or otherwise reacquired any of its shares or other securities.

 

2.9           Intentionally
left blank. 

 

2.10         Undisclosed
Liabilities. As of the Closing Date, CureDM has no debts, liabilities or obligations of any nature (whether accrued, absolute,
contingent, direct, indirect, unliquidated or otherwise and whether due or to become due) arising out of transactions entered into
on or prior to the Closing Date, or any transaction, series of transactions, action or inaction occurring on or prior to the Closing
Date, except for such debts, liabilities or obligations set forth on the CureDM Financial Statements or otherwise arising in the
ordinary course of business.

 

2.11         Intentionally
left blank. 

 

2.12         Absence
of Certain Changes or Events. Since September 30, 2017, there has not been (a) any change in the business, prospects, the
financial or other condition, or the respective assets or liabilities of CureDM as reflected in the CureDM Financial Statements
(as defined below) which would have a Material Adverse Effect on CureDM taken as a whole, or (b) any material loss sustained by
CureDM, including, but not limited to any loss on account of theft, fire, flood, explosion, accident or other calamity, whether
or not insured, which has or would be reasonably likely to have a Material Adverse Effect on CureDM.

 

2.13         Real
Property.

 

(a)       CureDM
does not own, and has never owned, any real property, and CureDM is not obligated and does not have an option to acquire an ownership
interest in any real property.

 

(b)       Schedule
2.13(b) sets forth a true, correct and complete list of the leased real property (the “Leased Real Property”)
and the leases under which such leased real property is leased, subleased or licensed, including all amendments or modifications
to such leases (the “Leases”). CureDM has provided to BTHE true, correct and complete copies of all Leases.

 

    7 

     

    

 

2.14         Personal
Property.

 

(a)       All
items of equipment and other tangible personal property and assets owned by or leased to CureDM: (i) are reasonably adequate for
the uses to which they are being put, (ii) are in good operating condition, maintenance and repair, subject to ordinary wear and
tear, (iii) were acquired and are usable in the ordinary course of business consistent with past practice, and (iv) are adequate
for the conduct of the business of CureDM in the manner in which such business is being conducted by CureDM as of the Closing Date.
All of the tangible personal property and assets of CureDM are located at the Leased Real Property.

 

(b)       Schedule
2.14(b) sets forth all assets that are material to the business of CureDM and that are being leased or licensed to the
CureDM for which the annual rental payment for each such asset exceeds $25,000. Except as set forth on Schedule 2.14(b),
no individual, partnership, corporation, limited liability company, association, joint venture, joint-stock company, trust, unincorporated
organization, governmental body or other entity (each, a “Person”) other than CureDM owns any equipment
or other tangible personal property or asset that is necessary to the operation of CureDM’s business as currently conducted.

 

(c)       Schedule
2.14(c) sets forth a true, correct and complete list and general description of each item of tangible personal property
of CureDM having a book value of greater than $25,000.

 

2.15         Tax
Matters. CureDM has filed all federal income tax returns and all other material tax returns that it was required to file
since the date of its organization, except insofar as such failure would not result in a Material Adverse Effect on CureDM. CureDM
has paid all taxes that it was required to pay since the date of its organization except for such taxes, if any, as are being contested
in good faith and as to which adequate reserves have been established by CureDM. CureDM is not currently the beneficiary of any
extension of time within which to file any tax return. There are no liens for taxes (other than taxes not yet due and payable)
upon any of the assets of CureDM. To CureDM’s knowledge, there is no material dispute or claim concerning any tax liability
of CureDM claimed or raised by any taxation authority in writing.

 

2.16         Financial
Statements. Schedule 2.16 contains copies of (a) the audited balance sheets of the Company as of December
31, 2016 and December 31, 2015, and the related statement of operations and members’ equity and statements of cash flows
for the fiscal years then ended, and (b) the unaudited balance sheet of the Company as of September 30, 2017, and the related statement
of operations and members’ equity and statement of cash flows for the nine month period then ended (collectively, the “CureDM
Financial Statements”).

 

2.17         Contracts.
A copy of each of CureDM’s material contracts, instruments, and agreements (collectively, the “CureDM Contracts”),
has been provided to BTHE. Each of the CureDM Contracts is a valid and binding obligation of CureDM and is in full force and effect,
except for where the failure to be in full force and effect would not, individually or in the aggregate, have a Material Adverse
Effect on CureDM. There are no existing defaults by CureDM thereunder or, to the knowledge of CureDM, by any other party thereto,
which defaults, individually or in the aggregate, would have a Material Adverse Effect on CureDM. As used herein, “CureDM
Contracts” shall include only those material agreements that would be required to be filed with the SEC pursuant to Item
601(b)(1) of Regulation S-K if CureDM was subject to the reporting requirements of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”).

 

    8 

     

    

 

2.18         Insurance.

 

(a)       True
and complete copies of all policies of property and other forms of insurance held by CureDM have been delivered to BTHE. 

 

(b)       There
is no material claim pending under any of such policies as to which coverage has been questioned, denied or disputed in writing
by the underwriters of such policies. All premiums due and payable under all such policies have been paid and CureDM is otherwise
in compliance in all material respects with the terms of such policies. CureDM has not received any written notice of any threatened
termination of, or material premium increase with respect to, any of such policies.

 

2.19         Anticorruption.

 

(a)       
Neither CureDM, nor, to the knowledge of CureDM, any of its directors or officers is or has at any time engaged in any activity,
practice or conduct which would constitute a violation of any applicable U.S. laws relating to anti-bribery, anti-corruption, anti-money
laundering or illegal payments and bribes and illegal political contributions and similar statutes, rules and regulations.

 

(b)           To
CureDM’s knowledge, neither CureDM nor any of its directors or officers is currently the subject of any investigation, inquiry
or enforcement proceedings by any governmental, administrative or regulatory body related to any applicable laws relating to anti-bribery,
anti-corruption, anti-money laundering, illegal payments and bribes and illegal political contributions and similar statutes, rules
and regulations, and no such investigation, inquiry or proceedings has been threatened, to CureDM’s knowledge, or is pending.

 

(c)           Without
limiting the generality of the foregoing, neither CureDM nor, to CureDM’s knowledge, any of its directors or officers has
offered, paid, promised to pay, or authorized the payment of any money, or offered, given, promised to give, or authorized the
giving of anything of value to: (i) any government or similar official for purposes of (A)(1) influencing any act or decision of
such official in his or her official capacity, (2) inducing such official to do or omit to do any act in violation of the lawful
duty of such official, or (3) securing any improper advantage; or (B) inducing such official to use his or her influence with a
governmental authority to affect or influence any act or decision of such governmental authority; or (ii) any person, while knowing
that all or a portion of such money or thing of value will be offered, given, or promised, directly or indirectly, to any official,
to any political party or official thereof, or to any candidate for political office, for purposes of (A)(1) influencing any act
or decision of such official, political party, party official, or candidate in his or her or its official capacity, (2) inducing
such official, political party, party official, or candidate to do or omit to do any act in violation of the lawful duty of such
official, political party, party official, or candidate, or (3) securing any improper advantage; or (B) inducing such official,
political party, party official, or candidate to use his or her or its influence with a governmental authority to affect or influence
any act or decision of such governmental authority. There have not been any false or fictitious entries made in the books or records
of CureDM, to its knowledge, relating to any offer, payment, promise to pay, or authorization of the payment of any money, or offer,
gift, promise to give, or authorization of the giving of anything of value, including any bribe, kickback or other illegal or improper
payment, and CureDM, has not established or maintained a secret or unrecorded fund.

 

    9 

     

    

 

2.20         Environmental
Matters. 

 

(a)       CureDM
is in compliance with all applicable environmental laws, which compliance includes the possession by CureDM of all governmental
authorizations required under applicable environmental laws, and compliance with the terms and conditions thereof, except, in each
case, except where non-compliance would not reasonably be expected to result in a Material Adverse Effect on CureDM. All applications
required to have been filed for the renewal of such governmental authorizations have been duly filed on a timely basis with the
appropriate governmental bodies, and each other notice or filing required to have been given or made with respect to such governmental
authorizations has been duly given or made on a timely basis with the appropriate governmental body.

 

(b)       CureDM
has not received any written notice from a governmental body that has led CureDM to believe that CureDM is not in material compliance
with, or that it has any material liability under, any environmental law.

 

2.21         Employee
Matters. CureDM does not have any employees. 

 

2.22         Bank
Accounts. CureDM has delivered to BTHE a list identifying each account maintained by or for
the benefit of CureDM at any bank or other financial institution, including, with respect to each such account, (a) the name of
the bank or financial institution, (b) the account number, (c) the balance as of the date of this Agreement (and whether any cash
comprising such balances is “restricted cash”), and (d) the names of all individuals authorized to draw on or make
withdrawals from such accounts.

 

2.23         Regulatory
Filings. CureDM has made all required registrations and filings with and submissions to all applicable governmental bodies
relating to the operation of the business of CureDM. There is no materially false or misleading information or significant omission
in any product application or other submission to the U.S. Food and Drug Administration (the “FDA”) or any other
comparable governmental body. All such registrations, filings and submissions were in compliance in all material respects with
all applicable laws when filed. No material deficiencies have been asserted by any such applicable governmental bodies with respect
to such registrations, filings or submissions and, to the knowledge of CureDM, no facts or circumstances exist which could indicate
that a material deficiency may be asserted by any such authority with respect to any such registration, filing or submission. CureDM
has delivered to BTHE copies of (a) all material reports of inspection observations, (b) all material establishment inspection
reports, (c) all material warning letters, and (d) any other material documents received by CureDM from the FDA or any other comparable
governmental body relating to the business of CureDM that assert ongoing material lack of compliance with any laws (including regulations
promulgated by the FDA and any other comparable governmental body) by CureDM.

 

    10 

     

    

 

2.24         Product
Candidates.

 

(a)       CureDM’s
clinical-stage products are being, and at all times have been, developed, tested, manufactured, processed, labeled, stored, transported
and distributed, as applicable, in compliance in all material respects with all applicable laws, including those requirements relating
to good manufacturing practices, good laboratory practices and good clinical practices applicable at the appropriate times.

 

(b)       The
pre-clinical and clinical trials conducted by or on behalf of CureDM were, and if still pending, are, being conducted in all material
respects in accordance with all applicable clinical protocols, informed consents and applicable laws. CureDM has not been notified
by the FDA or any other comparable governmental body of any restriction on the pre-clinical or clinical trials conducted or currently
being conducted by or on behalf of CureDM. Schedule 2.24(b), contains a descriptions of, protocols for, and data
and other results of, the pre-clinical and clinical trials conducted or currently being conducted by or on behalf of CureDM that
have been provided to BTHE which includes the location of the registered file and the identification of the party that has verified
such protocol and data. The descriptions of, protocols for, and data and other results of, the pre-clinical and clinical trials
conducted or currently being conducted by or on behalf of CureDM that have been provided to BTHE are true, correct and complete.

 

(c)       CureDM
has, where required, fulfilled and performed its obligations under each FDA registration (collectively, the “CureDM
FDA Registrations” and each a “CureDM FDA Registration”) in all material respects, and,
to the knowledge of CureDM, no material event has occurred or condition or state of facts exists that could constitute a breach
or default or could cause revocation, suspension, limitation or termination of any such CureDM FDA Registration or would reasonably
be expected to result in any other material impairment of the rights of the holder of any such CureDM FDA Registration. No loss
or expiration of any CureDM FDA Registration is pending or, to the knowledge of CureDM, threatened, other than expiration of any
CureDM FDA Registration in accordance with the terms thereof, and, to the knowledge of CureDM, there is no circumstance that could
reasonably be expected to cause such CureDM FDA Registration to not be renewable upon expiration to the extent permitted by law,
as needed. To the knowledge of CureDM, any third-party that is a supplier, manufacturer, or contractor for CureDM is in material
compliance with all CureDM FDA Registrations and the authorizations, approvals, licenses, permits, certificates, or exemptions
(including, without limitation, pre-market approval applications, pre-market notifications, investigational new drug applications,
new drug applications, biologic license applications, manufacturing approvals and authorizations, pricing and reimbursement approvals,
labeling approvals or their foreign equivalent) held by CureDM that are required for, among other things, the research, development,
manufacture, processing, labeling, distribution, marketing, storage, transportation, use, sale and provision of the products and
services of CureDM, of any comparable governmental body.

 

    11 

     

    

 

(d)       Schedule
2.24(d) sets forth a true, correct and complete list of all of CureDM’s products and product candidates, noting,
where applicable, (i) the phase of clinical trial or development each product or product candidate is in, and (ii) those products
or product candidates where FDA and/or other regulatory approval, including foreign approvals, has been applied for and/or received,
and listing the application made and/or the approval or decision thereon obtained. CureDM has made available to BTHE true, correct
and complete electronic copies of (A) any investigational new drug applications or new drug applications submitted to the FDA or
any other governmental body by or on behalf of CureDM, including any supplements thereto, (B) all final study results and/or reports
relating to products or product candidates, (C) all correspondence to or from CureDM (or its investigators) and the FDA or other
comparable governmental bodies, including meeting minutes and records of material contacts, (D) all documents in CureDM’s
possession related to inspections by the FDA or other comparable governmental bodies, and (E) all information relating to adverse
drug experiences obtained or otherwise received by CureDM from any source with respect to CureDM’s products or product candidates.

 

2.25         Full
Disclosure. No representation or warranty by CureDM in this Agreement or in any document or schedule to be delivered by
any such entity pursuant hereto, and no written statement, certificate or instrument furnished or to be furnished to BTHE pursuant
hereto or in connection with the negotiation, execution or performance of this Agreement contains, or will contain, any untrue
statement of a material fact or omits, or will omit, to state any fact necessary to make any statement herein or therein, in light
of the circumstances under which it was made, not materially misleading or necessary to a complete and correct presentation of
all material aspects of the businesses of CureDM.

 

SECTION 3

REPRESENTATIONS, COVENANTS, AND WARRANTIES

OF BTHE

 

BTHE hereby represents
and warrants to CureDM and the CureDM Members that, except as set forth in the correspondingly numbered section of the disclosure
schedule attached hereto (the “BTHE Disclosure Schedule”), the statements contained in this Section 3
are true and correct in all material respects as of the Closing Date and as of each Milestone Achievement Date. The BTHE Disclosure
Schedule shall be arranged in sections corresponding to the sections contained in this Section 3. For purposes of this Section
3, the phrase “to the knowledge of BTHE” or any phrase of similar import shall be deemed to refer to the actual or
constructive knowledge of Carl W. Rausch after due inquiry of items included in the BTHE SEC Documents.

 

3.1           Organization
and Good Standing. BTHE is a corporation duly organized, validly existing and in good standing under the laws of the State
of Delaware. BTHE is entitled to own or lease its properties and to carry on its business as and in the places where such properties
are now owned, leased or operated and such business is now conducted and BTHE is qualified to do business as a foreign corporation
in each jurisdiction, if any, in which its property or business requires such qualification except for any such failure, which
when taken together with all other failures, is not likely to have a Material Adverse Effect on the business of BTHE taken as a
whole.

 

    12 

     

    

 

3.2           Authorization;
Enforceability; No Breach. BTHE has all the necessary corporate power and authority to execute and deliver this Agreement
and perform its respective obligations hereunder in accordance with the terms hereof. This Agreement has been duly executed by
BTHE and constitutes the legal, valid and binding obligation of BTHE, enforceable against it in accordance with its terms, except
as may be limited by bankruptcy, moratorium, insolvency or other similar laws generally affecting the enforcement of creditors’
rights. The execution and delivery of this Agreement by BTHE does not, and the performance of BTHE’s obligations hereunder
and the consummation of the transactions contemplated hereby will not:

 

(a)       violate
any provision of the Certificate of Incorporation or By-Laws of BTHE (collectively, the “BTHE Organizational Documents”);

 

(b)       violate,
conflict with or result in the breach of any of the terms of, result in a material modification of, otherwise give any other contracting
party the right to terminate, or constitute (or with notice or lapse of time or both constitute) a default under, any contract
or other agreement to which BTHE is a party or by or to which it or any of its assets or properties may be bound or subject;

 

(c)       violate
any order, judgment, injunction, award or decree of any court, arbitrator or governmental or regulatory body against, or binding
upon, BTHE or upon the properties or business of BTHE; or

 

(d)       To
BTHE’s knowledge, violate any statute, law or regulation of any jurisdiction, which could have
a Material Adverse Effect on BTHE. As used herein “Material Adverse Effect on BTHE” shall mean
any effect or change that would be materially adverse to the business, assets, condition (financial or otherwise), operating results
or operations of BTHE or on the ability of BTHE to consummate timely the transactions contemplated hereby, as the context requires.

 

3.3           Compliance
with Laws. BTHE, to its knowledge, has complied with all federal, state, county and local laws, ordinances, regulations,
inspections, orders, judgments, injunctions, awards or decrees applicable to its business except for such non-compliance that would
not have a Material Adverse Effect on BTHE.

 

3.4           Litigation;
Actions and Proceedings. Except as disclosed in the BTHE SEC Documents (as defined below), there is no outstanding order,
judgment, injunction, award or decree of any court, governmental or regulatory body or arbitration tribunal against or involving
BTHE. Except as disclosed in the BTHE SEC Documents, there is no action, suit, investigation or proceeding pending or, to BTHE’s
knowledge, threatened at law or in equity, before any arbitrator, court or other governmental authority nor any judgment, decree,
injunction, award or order outstanding, against BTHE or its respective properties or rights which could reasonably be expected
to have a Material Adverse Effect on BTHE.

 

    13 

     

    

 

3.5           Brokers
or Finders. No broker’s or finder’s fee will be payable by BTHE in connection with the transaction contemplated
by this Agreement, nor will any such fee be incurred as a result of any actions by BTHE.

 

3.6           BTHE
Shares. The BTHE Shares have been reserved and duly authorized by all necessary corporate actions, and when issued in accordance
with the terms of this Agreement, the BTHE Shares will be validly issued, fully paid and non-assessable. The issuance of BTHE Shares
to the CureDM Members pursuant to this Agreement will not violate any pre-emptive or similar rights of any Person.

 

3.7           Books
and Records. To BTHE’s knowledge, the books and records, financial and otherwise, of BTHE are in all material respects
complete and correct and have been made and maintained in accordance with sound business and bookkeeping practices and, in reasonable
detail, accurately and fairly reflect the transactions and the assets of BTHE.

 

3.8           Corporate
Records; Minute Book. The minute book of BTHE contains, as of the Closing Date, evidence of the due election and incumbency
of the board of directors of BTHE (the “Board of Directors of BTHE”) and officers of BTHE executing this
Agreement or any document, certificate, or other instrument executed in order to consummate the transactions herein contemplated
together with an accurate, up to date and complete record of the proceedings of all meeting of directors, committees thereof, or
stockholders and all written consents in lieu thereof. There have been no formal meetings
or other proceedings of the shareholders of BTHE, the Board of Directors of BTHE or any committee of the Board of Directors of
BTHE that are not reflected in BTHE Organizational Documents or the BTHE minute book (collectively, the “BTHE Constitutional
Documents”). To the knowledge of BTHE, there has not been any material violation of the BTHE Constitutional Documents,
and BTHE has not taken any action that is inconsistent with the BTHE Constitutional Documents. To the knowledge of BTHE, BTHE is
not in any material default under or in violation of any provision of its Organizational Documents. BTHE has provided to
CureDM true, correct and complete copies of the BTHE Organizational Documents as in effect on the date of this Agreement.

 

3.9           Stockholders’
List. The stockholders’ list of BTHE, which has been previously delivered by BTHE to CureDM, is a true and accurate
copy thereof as of the date indicated thereon. BTHE’s transfer agent (“Transfer Agent”) retains
in safekeeping all certificates that have been or should be canceled on the registration of transfer thereof. All of such canceled
certificates have on their face in conspicuous permanent ink or perforations the word “canceled.” All of such certificates
are accounted for as either canceled and in the possession of the Transfer Agent, outstanding, or unissued. To the best of BTHE’s
knowledge, except for securities broker-dealers, clearing agencies, securities depositories, banks, or other securities industry
entities registered with the SEC whose regular business consists of holding securities beneficially owned by others, each stockholder
listed on such stockholders’ list is the beneficial owner thereof, and such stockholder is not a party to, and such stockholder’s
stock is not subject to, any agreement, understanding, power-of-attorney, or other arrangement of any kind with any person who
is an affiliate of BTHE or acting in concert with such affiliate under which such affiliate or person acting in concert with such
affiliate has or shares investment or voting power over such securities. Except as disclosed in the SEC Documents, BTHE has not
granted, issued or agreed to grant, issue or make available any warrants, options, subscription rights or any other commitments
of any character relating to the securities of BTHE. All of the outstanding shares of BTHE stock are duly authorized and validly
issued, fully paid and non-assessable. BTHE is not a party to or bound by any, and to the
knowledge of BTHE there are no, agreements or understandings with respect to the voting (including pooling agreements, voting trusts
and proxies) or sale or transfer (including agreements imposing transfer restrictions) of any equity interests of BTHE. 

 

    14 

     

    

 

3.10         SEC
Reports and Financial Statements.

 

(a)       BTHE
has filed or furnished all forms, documents and reports required to be filed or furnished by it (the “BTHE SEC Documents”)
with the U.S. Securities and Exchange Commission (the “SEC”). As of their respective dates or, if amended,
as of the date of such amendment, the BTHE SEC Documents complied in all material respects with the requirements of the Securities
Act, the Exchange Act and the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), as the case may
be, and the applicable rules and regulations promulgated thereunder, and none of the BTHE SEC Documents as of the Closing Date
contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to
make the statements therein, in light of the circumstances under which they were made, not misleading.

 

(b)       The
audited financial statements and unaudited interim financial statements (including all related notes and schedules) of BTHE included
in the BTHE SEC Documents (the “BTHE Financial Statements”) complied as to form in all material respects
with the rules and regulations of the SEC then in effect, fairly present in all material respects the financial position of BTHE,
as at the respective dates thereof, and the results of its operations and its cash flows for the respective periods then ended
(subject, in the case of the unaudited statements, to normal recurring year-end audit adjustments that were not or are not expected
to be, individually or in the aggregate, materially adverse to BTHE), and were prepared in accordance with United States generally
accepted accounting principles (“GAAP”) applied on a consistent basis during the periods involved (except
as may be indicated therein or in the notes thereto).

 

3.11         Compliance
with Securities Laws, Rules, and Regulations. All securities of BTHE issued since its inception have been initially issued
pursuant to and in compliance with applicable federal and state laws, rules, and regulations; specifically, all offers and sales
of shares of common voting stock by BTHE were made pursuant to exemptions from the registration requirements of Section 5 of the
Securities Act, and pursuant to available exemptions provided by applicable state securities laws. Further, BTHE has made all the
required filings with any federal or state regulatory agency regarding the offer and sale of all issued and outstanding shares
of common voting stock.

 

    15 

     

    

 

3.12         Absence
of Certain Changes or Events. Since September 30, 2017, there has not been (a) any material adverse change in the business,
prospects, the financial or other condition, or the assets or liabilities of BTHE as reflected in the BTHE Financial Statements,
(b) any material loss sustained by BTHE, including, but not limited to any loss on account of theft, fire, flood, explosion, accident
or other calamity, whether or not insured, or from any labor dispute or court dispute or government action, order or decree which
has or may have a Material Adverse Effect on BTHE, or (c) to the knowledge of BTHE, any event, condition or state of facts, including,
without limitation, the enactment, adoption or promulgation of any law, rule or regulation, the occurrence of which would have
a Material Adverse Effect on BTHE. BTHE has conducted its business in the ordinary course consistent with past practice in all
material respects. Without limiting the generality of the foregoing, since September 30, 2017, BTHE has not (except as disclosed
in the SEC Documents): (i) amended the BTHE Organizational Documents, provided, however, BTHE is currently in process of increasing
its authorized shares of common stock to 1,000,000,000; (ii) adopted a plan or agreement of liquidation, dissolution, restructuring,
merger, consolidation, recapitalization or other reorganization; (iii) issued any note, bond or other debt security or right to
acquire any debt security, incurred or guaranteed any indebtedness or entered into any “keep well” or other agreement
to maintain the financial condition of another person or other arrangement having the economic effect of actions any of the foregoing;
(iv) entered into or consummated any transaction involving the acquisition (including, by merger, consolidation or acquisition
of the business, stock or assets or other business combination) of any individual, partnership, corporation, limited liability
company, association, joint venture, joint-stock company, trust, unincorporated organization, governmental body or other entity
(other than in the ordinary course of business); (v) changed any of its material accounting policies or practices, except as required
as a result of a change in GAAP; or (vi) agreed or committed to do any of the foregoing.

 

3.13         Indebtedness.
The BTHE SEC Documents set forth all outstanding secured and unsecured Indebtedness of BTHE, or for which BTHE has commitments
as of the date hereof. For the purposes of this Agreement, “Indebtedness” shall mean (a) any liabilities for
borrowed money or amounts owed including trade accounts payable incurred in the ordinary course of business, (b) all guaranties,
endorsements and other contingent obligations in respect of Indebtedness of others, whether or not the same should be reflected
in BTHE’s consolidated balance sheet; and (c) the present value of any lease payments due under leases required to be capitalized
in accordance with GAAP.

 

3.14         State
Takeover Statutes. No “fair price,” “moratorium,” “control share acquisition” or other
similar antitakeover statue or regulation enacted under state or federal laws in the United States, is applicable to the transactions
contemplated by this Agreement.

 

3.15         Tax
Matters. BTHE has filed all federal income tax returns and all other material tax returns that it was required to file
since the date of its incorporation. BTHE has paid all taxes that it was required to pay since the date of its incorporation BTHE
is not currently the beneficiary of any extension of time within which to file any tax return. There are no liens for taxes (other
than taxes not yet due and payable) upon any of the assets of BTHE. There is no material dispute or claim concerning any tax liability
of BTHE either (i) claimed or raised by any taxation authority in writing or (ii) as to which BTHE has knowledge.

 

    16 

     

    

 

3.16         Anticorruption.

 

(a)       Neither
BTHE nor any of its directors, officers, employees, representatives, or any person generally acting by or on behalf of any of the
aforementioned, is or has at any time engaged in any activity, practice or conduct which would constitute an offence under all
applicable laws relating to anti-bribery, anti-corruption, anti-money laundering or illegal payments and bribes and illegal political
contributions and similar statutes, rules and regulations.

 

(b)       BTHE
has in place adequate procedures to prevent any conduct of the kind referred to in Section 3.16(a) above.

 

(c)       Neither
BTHE nor any of its directors, officers, employees, representatives, or any person generally acting by or on behalf of any of the
aforementioned, is or has been the subject of any investigation, inquiry or enforcement proceedings by any governmental, administrative
or regulatory body or any customer regarding any offence or alleged offence under applicable laws relating to anti-bribery, anti-corruption,
anti-money laundering, illegal payments and bribes and illegal political contributions and similar statutes, rules and regulations,
and no such investigation, inquiry or proceedings have been threatened or are pending and there are no circumstances likely to
give rise to any such investigation, inquiry or proceedings.

 

(d)       Without
limiting the generality of the foregoing, neither BTHE nor any of its directors, officers, employees, representatives, or any person
generally acting by or on behalf of any of the aforementioned, has corruptly or otherwise offered, paid, promised to pay, or authorized
the payment of any money, or offered, given, promised to give, or authorized the giving of anything of value to: (i) any government
or similar official for purposes of (A)(1) influencing any act or decision of such official in his or her official capacity, (2)
inducing such official to do or omit to do any act in violation of the lawful duty of such official, or (3) securing any improper
advantage; or (B) inducing such official to use his or her influence with a governmental authority to affect or influence any act
or decision of such governmental authority; or (ii) any person, while knowing that all or a portion of such money or thing of value
will be offered, given, or promised, directly or indirectly, to any official, to any political party or official thereof, or to
any candidate for political office, for purposes of (A)(1) influencing any act or decision of such official, political party, party
official, or candidate in his or her or its official capacity, (2) inducing such official, political party, party official, or
candidate to do or omit to do any act in violation of the lawful duty of such official, political party, party official, or candidate,
or (3) securing any improper advantage; or (B) inducing such official, political party, party official, or candidate to use his
or her or its influence with a governmental authority to affect or influence any act or decision of such governmental authority.
There has been no false or fictitious entries made in the books or records of BTHE relating to any offer, payment, promise to pay,
or authorization of the payment of any money, or offer, gift, promise to give, or authorization of the giving of anything of value,
including any bribe, kickback or other illegal or improper payment, and BTHE has not established or maintained a secret or unrecorded
fund.

 

3.17         Full
Disclosure. No representation or warranty by BTHE in this Agreement or in any document or schedule to be delivered by it
pursuant hereto, and no written statement, certificate or instrument furnished or to be furnished by BTHE pursuant hereto or in
connection with the negotiation, execution or performance of this Agreement contains, or will contain, any untrue statement of
a material fact or omits, or will omit, to state any fact necessary to make any statement herein or therein, in light of the circumstances
under which it was made, not materially misleading or necessary to a complete and correct presentation of all material aspects
of the businesses of BTHE.

 

    17 

     

    

 

3.18         Private
Offering. No form of general solicitation or general advertising was used by BTHE, or to the knowledge of BTHE, its authorized
representatives, in connection with the offer or sale of the securities to be issued under this Agreement. Assuming the accuracy
of the representations and warranties of the CureDM and the CureDM Members set forth in Sections 2 and 4, respectively, the issuance
of common stock pursuant to this Agreement is exempt from the registration requirements of the Securities Act, and neither BTHE
nor, to the knowledge of BTHE, any authorized representative acting on its behalf, has taken or will take any action hereafter
that would cause the loss of such exemption. BTHE agrees that neither it, nor anyone authorized to act on its behalf, has offered
or will offer to sell the BTHE Shares or any other securities of BTHE so as to require the registration of the BTHE Shares being
offered hereby pursuant to the provisions of the Securities Act or any state securities laws. Neither BTHE nor any of its affiliates,
directly or indirectly through any agent, sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of
any security that is or will be integrated with the issuance of common stock under this Agreement in a manner that would require
registration of the BTHE Shares under the Securities Act.

 

3.19         No
Restrictions on Common Stock. Except as expressly set forth in SEC Documents, (a) no Person has the right, contractual
or otherwise, to cause BTHE to issue or sell to it any shares of common stock or shares of any other capital stock or other equity
interests of BTHE and (b) no Person has any purchase option, call option, preemptive rights, resale rights, subscription rights,
rights of first refusal or other rights to purchase any shares of common stock or shares of any other capital stock of or other
equity interests in BTHE.

 

3.20         No
Manipulation. BTHE has not taken and will not, in violation of applicable law, take any action designed to or that might
reasonably be expected to cause or result in stabilization or manipulation of the price of its stock to facilitate the sale or
resale of the BTHE Shares.

 

3.21         Independent
Auditors. Liggett & Webb, P.A., whose audit report on the consolidated financial statements of BTHE as of and for the
years ended December 31, 2016 and December 31, 2015 is included in the applicable SEC Documents, is an independent registered public
accountant as required by the Securities Act and by the rules of the Public Company Accounting Oversight Board.

 

3.22         No
Undisclosed Liabilities. BTHE does not have any obligation or liability required by GAAP to be recognized on a condensed
consolidated statement of financial position of BTHE, except (a) as incurred since September 30, 2017 in the ordinary course of
business or as have been otherwise disclosed in the SEC Documents, (b) as have been discharged or paid in full in the ordinary
course of business since September 30, 2017, (c) as incurred in connection with the transactions contemplated by this Agreement,
(d) that are obligations to perform pursuant to the terms of any of material contracts and (e) as would not constitute a Material
Adverse Effect on BTHE.

 

    18 

     

    

 

3.23         Accounting
Controls. Except as disclosed in the SEC Documents, BTHE maintains a system of internal accounting controls to provide
reasonable assurance that (a) transactions are executed in accordance with management’s general or specific authorization;
(b) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain
accountability for assets; (c) access to assets is permitted only in accordance with management’s general or specific authorization;
and (d) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action
is taken with respect to any differences.

 

3.24         Disclosure
Controls. Other than as disclosed in the SEC Documents, (a) BTHE has established and maintains and evaluates “disclosure
controls and procedures” (as such term is defined in Rule 13a-15 and Rule 15d-15 under the Exchange Act); (b) such disclosure
controls and procedures are designed to ensure that material information relating to BTHE is made known to BTHE’s Chief Executive
Officer and its Chief Financial Officer by others within those entities, and such disclosure controls and procedures are effective
to perform the functions for which they were established; and (c) BTHE’s auditors and the Board of Directors of BTHE have
been advised of: (i) any significant deficiencies and material weaknesses in the design or operation of internal controls which
are reasonably likely to adversely affect BTHE’s ability to record, process, summarize and report financial data and (ii)
any fraud, whether or not material, that involves management or other employees who have a role in BTHE ‘s internal controls.
As of the date hereof, BTHE has no knowledge of any reason that its outside auditors and its Chief Executive Officer and Chief
Financial Officer shall not be able to give the certifications and attestations required pursuant to the rules and regulations
adopted pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, without qualification, when next due. Since the date of the
most recent evaluation of such disclosure controls and procedures, there have been no changes in internal controls or in other
factors within control of BTHE that have materially affected, or are reasonably likely to materially affect, BTHE’s internal
controls. BTHE and its officers and directors, in their capacities as such, are in compliance in all material respects with the
provisions of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated thereunder that are applicable to BTHE or
such officers and directors, including Section 402 related to loans and Sections 302 and 906 related to certifications.

 

3.25         Contracts.
None of the contracts or agreements (which, for the avoidance of doubt, do not include any filings under Item 601(b)(3) of Regulation
S-K under the Securities Act) filed as an exhibit to BTHE’s Annual Report on Form 10-K for the fiscal year ended December
31, 2016, Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2017, or any Quarterly Report on Form 10-Q or
Current Report on Form 8-K subsequent thereto, have been terminated, materially amended, modified, supplemented or waived, except
as disclosed in the SEC Documents or except as are required to be filed under Item 601 of Regulation S-K under the Securities Act
and have terminated in accordance with their terms; BTHE has not sent or received any communication regarding the termination,
amendment, modification, supplementation or waiver of, or an intention to terminate, materially amend, modify, supplement or waive,
or not to consummate any transaction contemplated by, any such contract or agreement; and no such termination, amendment, modification,
supplementation or waiver, or intention to terminate, amend, modify, supplement or waive, or not to consummate any transaction
contemplated by, any such contract or agreement has been threatened by BTHE or, to BTHE’s knowledge, any other party to any
such contract or agreement.

 

    19 

     

    

 

3.26         Acknowledgement
of CureDM and CureDM Member Representations. BTHE acknowledges and agrees that none of CureDM or any CureDM Member makes,
nor has any of the foregoing made, any representations or warranties with respect to the transactions contemplated hereby other
than those specifically set forth in Sections 2 and 4, as applicable.

 

3.27         Removal
of Legend. On and after such date as the BTHE Shares held by CureDM, any CureDM Member, or any of its or their successors
and permitted assigns (each, a “Seller”) are eligible for sale under Rule 144 and in connection with
any such sale of BTHE Shares by a Seller in reliance on Rule 144 under the Securities Act, the applicable Seller or its broker
shall deliver to BTHE and the transfer agent a customary broker representation letter and a certificate of the Seller providing
any information that BTHE and the transfer agent deem reasonably necessary to determine that the sale of the BTHE Shares is made
in compliance with Rule 144, including, as may be appropriate, a certification (a) that such Seller is not (and in the preceding
three months has not been) an “affiliate” of BTHE, as that term is defined under Rule 144, (b) regarding the length
of time the BTHE Shares have been held and (c) that the Seller is not in possession of material non-public information relating
to BTHE. Upon receipt of such representation letter and certificate and if BTHE determines that the sale may be made pursuant with
Rule 144, BTHE shall as soon as reasonably practicable cause the removal of such notation of a restrictive legend from the Seller’s
book-entry account maintained by the Transfer Agent in connection with such sale.

 

3.28         Investment
Company; Passive Foreign Investment Company. BTHE is not and, after giving effect to the issuance of the BTHE Shares will
not be, an “investment company” required to register under the Investment Company Act of 1940, as amended. BTHE does
not believe that it is a “passive foreign investment company” as such term is defined in the Internal Revenue Code
of 1986, as amended from time to time, and the regulations promulgated thereunder (the “Code”).

 

3.29         Title
to Real and Personal Property. BTHE has, with such exceptions as are described in the SEC Documents or are not material
and do not interfere with the intended use to be made of such property by BTHE, (a) in the case of owned real property, good and
marketable fee title to, and (b) in the case of owned personal property, good and valid title to, or, in the case of leased real
or personal property, valid and enforceable leasehold interests (as the case may be) in, all of its properties and assets, tangible
and intangible.

 

3.30         Compliance
with Environmental Laws. Except to the extent the failure to comply with the following could not reasonably be expected
to have a Material Adverse Effect on BTHE, (a) the operations of BTHE, to BTHE’s knowledge, comply with all applicable environmental
laws, all necessary environmental permits have been obtained and are in effect for the operations and properties of BTHE and BTHE
is in compliance in all material respects therewith and (b) BTHE has not received any notice in writing that it or any of its affiliates
is potentially liable for the remedial or other costs with respect to treatment, storage, disposal, release, arrangement for disposal
or transportation of any environmentally sensitive material, except for costs incurred in the ordinary course of business with
respect to treatment, storage, disposal or transportation of such environmentally sensitive material.

 

    20 

     

    

 

3.31         Intellectual
Property; Privacy.

 

(a)       BTHE
owns all of the Intellectual Property used in, or necessary for, the operation of the business as conducted as of the date hereof,
and as proposed to be conducted (collectively, the “BTHE Intellectual Property”),
free and clear of any encumbrance. The BTHE Intellectual Property owned by BTHE are set forth in the BTHE SEC Documents. The use
of the BTHE Intellectual Property in the conduct of BTHE’s business or operations as currently conducted has not and does
not materially infringe, violate or misappropriate any Intellectual Property of any third party. There is no claim or litigation
pending or, to the knowledge of BTHE, threatened against BTHE alleging that the use of the BTHE Intellectual Property in the conduct
of BTHE’s business or operations as currently conducted infringes, violates or misappropriates any Intellectual Property
of any third party or otherwise challenging the use, ownership, licensing, validity or enforceability of any BTHE Intellectual
Property owned (or purported to be owned) by BTHE.

 

(b)       All
employees, consultants and other persons who materially contributed to the conception, creation or development of any of the BTHE
Intellectual Property owned (or purported to be owned) by BTHE did so either (i) within the scope of his or her employment such
that, subject to and in accordance with applicable laws, all Intellectual Property rights arising therefrom became exclusively
owned by BTHE, or (ii) pursuant to valid and enforceable written agreements assigning all Intellectual Property rights therein
to BTHE. BTHE has taken all commercially reasonable efforts to maintain the confidentiality of all material trade secrets of BTHE.

 

(c)       BTHE
is in material compliance with all applicable Privacy Laws. BTHE has taken all commercially reasonable measures necessary or appropriate
to protect and maintain the confidentiality of all personally identifiable information and other confidential customer information
collected by BTHE and to maintain the security of its data storage practices, in each case, in accordance with all Privacy Laws.
BTHE has not received written notice of any claims or been charged with any violation of any Privacy Laws or any failure to adequately
protect or maintain the confidentiality of any personally identifiable information and other confidential customer information.
BTHE is not aware of any data breaches involving any personally identifiable information collected by BTHE.

 

3.32         Insurance.

 

(a)       True
and complete summaries, including policy numbers, of property and other forms of insurance held by BTHE have been delivered to
CureDM. 

 

(b)       There
is no material claim pending under any of such policies as to which coverage has been questioned, denied or disputed in writing
by the underwriters of such policies. All premiums due and payable under all such policies have been paid and BTHE is otherwise
in compliance in all material respects with the terms of such policies. BTHE has not received any written notice of any threatened
termination of, or material premium increase with respect to, any of such policies.

 

    21 

     

    

 

SECTION 4

REPRESENTATIONS, COVENANTS, AND WARRANTIES

OF THE CUREDM MEMBERS

 

Each of the CureDM
Members, severally and not jointly, hereby represents and warrants to BTHE as of the Closing Date, as follows:

 

4.1           Ownership
and Restrictions on CureDM Membership Interest. Such CureDM Member is not a party to any agreement, written or oral, creating
rights in respect of the CureDM Membership Interests owned by such CureDM Member in any third person or, except as set forth in
the CureDM Organizational Documents, relating to the voting of such CureDM Membership Interest. Such CureDM Member is the lawful
and beneficial owner of the CureDM Membership Interest set forth opposite such CureDM Member’s name on Schedule A
hereto, free and clear of all security interests, liens, encumbrances, equities and other charges, except for any applicable restrictions
under U.S. securities laws and under the CureDM Organizational Documents. There are no existing warrants, options, stock purchase
agreements, redemption agreements, restrictions of any nature, calls or rights to subscribe of any character relating to such CureDM
Membership Interest owned by such CureDM Member, nor does such CureDM Member hold any other securities convertible into membership
interests in CureDM.

 

4.2           No
Registration. Such CureDM Member understands that the issuance of the BTHE Shares will not be registered under the Securities
Act.

 

4.3           Power
and Authority. Such CureDM Member is authorized to enter into this Agreement and perform his, her or its obligations hereunder,
and no consent of any person is necessary in order for such CureDM Member to enter into and consummate the transactions contemplated
by this Agreement.

 

4.4           Investment
Intent. The BTHE Shares, when issued, will be acquired for such CureDM Member’s own account, for investment purposes
only and not with a view for distribution or resale to others. Such CureDM Member will not sell or otherwise transfer the BTHE
Shares unless such sale is made pursuant to an effective registration statement under the Securities Act or an exemption to or
exclusion from such registration requirement is available. BTHE is under no obligation to register the offer or sale of the BTHE
Shares under the Securities Act. Following the issuance of the BTHE Shares, legends shall be placed on the certificates representing
the BTHE Shares to the effect that they have not been registered under the Securities Act or applicable state securities laws and
appropriate notations thereof will be made in BTHE’s books and stop transfer instructions may be placed with BTHE’s
transfer agent. The acquisition of the BTHE Shares represents a high-risk capital investment, and such CureDM Member is able to
afford an investment in a speculative venture such as BTHE. Such CureDM Member has adequate means of providing for his, her or
its current financial needs and foreseeable contingencies and has no need for liquidity of its investment in the BTHE Shares for
an indefinite period of time. Although BTHE’s common stock is quoted for trading by a marketplace operated by OTC Markets
Group Inc., trading has been both low-volume and sporadic and there are no assurances a more robust trading market will develop
in the near future, if at all; accordingly, the BTHE Shares are considered an illiquid investment. Such CureDM Member is fully
aware that such investments can and sometimes do result in the loss of the entire investment. Such CureDM Member is an experienced
and sophisticated investor, is able to fend for himself, herself or itself in the transactions contemplated by this Agreement,
and has such knowledge and experience in financial and business matters that he, she or it is capable of evaluating the risks and
merits of acquiring the BTHE Shares. Such CureDM Member is an accredited investor as such term is defined under the Securities
Act, and understands the meaning of the term “accredited investor.” Each
CureDM Member who is not an accredited investor is listed
on Schedule 4.4 and either alone or with his, her or it representative(s) has such knowledge and experience in financial
and business matters that he, she or it is capable of evaluating the merits and risks of the prospective investment.
Such CureDM Member understands that the offer and sale of the BTHE Shares is being made only by means of this Agreement and that
BTHE has not authorized the use of, and such CureDM Member confirms that he, she or it is not relying upon, any other information,
written or oral, other than material contained in this Agreement and the BTHE SEC Documents.

 

    22 

     

    

 

4.5          Independent
Evaluation. Such CureDM Member conducted its own independent evaluation, made its own analysis and consulted with advisors
(including legal, accounting, and tax advisors) as it has deemed necessary, prudent or advisable in order for such CureDM Member
to make its own determination and decision to enter into the transactions contemplated by this Agreement and to execute and deliver
this Agreement.

 

4.6           Acknowledgement
of BTHE Representations. CureDM Members acknowledge and agree that BTHE does not make, nor has it made, any representations
or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.

 

SECTION 5

COVENANTS AND ADDITIONAL AGREEMENTS

 

5.1           Examinations
and Investigations. CureDM and the CureDM Members acknowledge that they have been entitled, through their employees and
representatives, to make such investigation and verification of the assets, properties, business and operations, books, records
and financial condition of BTHE, including communications with suppliers, vendors and customers, as they each may reasonably require.
BTHE acknowledges that it have been entitled, through its employees and representatives, to make such investigation and verification
of the assets, properties, business and operations, books, records and financial condition of CureDM, including communications
with suppliers, vendors and customers, as it may reasonably require. No investigation by a party hereto shall, however, diminish
or constitute a waiver of, in any way, any of the representations, warranties, covenants or agreements of any other party under
this Agreement.

 

5.2           Expenses.
Each party hereto agrees to pay its own costs and expenses incurred in negotiating this Agreement and consummating the transactions
described herein.

 

    23 

     

    

 

5.3           Further
Assurances. The parties shall execute such documents and other papers and take such further actions, as may be reasonably
required or desirable, to carry out the provisions hereof and the transactions contemplated hereby.

 

5.4           Confidentiality.
Each of the parties hereto agrees to keep confidential any confidential or proprietary information of the other party it obtains
in connection therewith; provided, however, such obligation shall not apply to information which:

 

 (a)       at
the time of disclosure was public knowledge;

 

 (b)       after
the time of disclosure becomes public knowledge (except due to the action of the receiving party); or

 

 (c)       the
receiving party had within its possession at the time of disclosure.

 

5.5           BTHE
Board Seat. CureDM shall have the right to appoint (1) director to the Board of Directors of BTHE (the “CureDM
Designee”). BTHE shall cause the CureDM Designee to be appointed to the Board of Directors of BTHE within thirty
(30) days following the Closing Date. BTHE shall nominate such CureDM Designee for election to the Board of Directors of BTHE for
at least two successive terms. In the event the Equity Financing (as defined below) is not closed as of the Equity Financing Date
(as defined below), then the CureDM Designee shall resign effectively immediately.

 

5.6           Equity
Financing; Unwinding; Lock Up. BTHE shall use its best efforts to secure a binding commitment to close an equity financing
with net proceeds of at least $1,000,000 (the “Equity Financing”) within 180 days after the Closing Date
(the “Equity Financing Date”). The use of the Equity Financing proceeds shall be designated as working
capital for at least, but not limited to the synthesis of HIP2B clinical material.1
In the event the Equity Financing is not closed as of the Equity Financing Date, then, if both BTHE and CureDM, Inc. mutually agree,
(i) this Agreement – other than the provisions of Section 13, will then be null and void and have no further force and effect
and all other rights and liabilities of the parties hereunder will terminate without any liability of any party to any other party
and (ii) each party shall have released, remised and forever discharged any and all rights and claims that it has had, now has
or might now have against the other. Further, the CureDM Members will return all BTHE Shares to BTHE for cancellation. The CureDM
Members will deliver all required documents required to cancel the BTHE Shares, including, but not limited to, a medallion guaranteed
stock power. The CureDM Members hereby appoint CureDM, Inc. as its agent in fact in order to implement the cancellation of the
BTHE Shares as contemplated herein and to sign all related documentation in connection with the cancellation of the BTHE Shares,
including, but not limited to, a medallion guaranteed stock power. Upon receipt of the BTHE Shares and all related documentation,
BTHE shall return all CureDM Membership Interest to the CureDM Members. In order to ensure compliance with this section, the CureDM
Members hereby agree that until the Equity Financing is closed, the CureDM Members shall not sell, offer to sell, contract to sell,
assign, pledge, hypothecate, encumber or otherwise transfer, or enter into any contract, option or other arrangement or understanding
with respect to the sale, assignment, pledge or other disposition of the BTHE Shares. The CureDM Members agree and acknowledge
that an appropriate restrictive legend will be placed on the certificates representing the BTHE Shares.

 

 

1
NTD: To discuss.

 

    24 

     

    

 

5.7           Employment
Matters. From and after the Closing, Carl W. Rausch will serve as Chief Executive Officer of CureDM and Loraine V. Upham
will serve as Chief Operating Officer of BTHE. In connection with the closing of the transactions contemplated hereby, Ms. Upham
and BTHE shall enter into an executive retention agreement to be effective on and after the Closing Date for a term of three (3)
years. Ms. Upham shall be granted stock options to acquire four million (4,000,000) shares of BTHE common stock at an exercise
price equal to the thirty (30) day average closing price immediately prior to execution of such retention agreement, which options
shall vest over a three (3) year period.

 

5.8           CureDM
Board. As of the Closing, each of the members of the Board of Directors of CureDM
shall resign and Carl W. Rausch shall be appointed as the sole director of CureDM. 

 

SECTION 6

INTENTIONALLY OMITTED

 

SECTION 7

INTENTIONALLY OMITTED

 

SECTION 8

CLOSING DELIVERABLES

 

8.1           Deliveries
of CureDM. At the Closing, CureDM shall deliver to BTHE:

 

(a)       a
good standing or similar certificate of CureDM with respect to the status of CureDM in Delaware and in each other jurisdiction
in which it is qualified to do business, in each case, certified by the Secretary of State of the other relevant authority not
more than ten days prior to the Closing Date;

 

(b)       a
copy of the certificate of formation of CureDM, certified by the Secretary of State of the State of Delaware not more than ten
days prior to the Closing Date; and

 

(c)       a
certificate, signed by the Secretary of CureDM, (i) certifying as true, accurate and complete the operating agreement of CureDM,
and any amendments thereto, (ii) certifying as true, accurate and complete copies of actions by written consent or resolutions
duly adopted by the Board of Directors of CureDM that authorize and approve the execution, delivery and performance of this Agreement
and the consummation of the transactions contemplated by this Agreement, and (iii) certifying the incumbency, signature and authority
of the officers of CureDM that are authorized to execute this Agreement and any other documents, instruments or agreements to be
executed and delivered by CureDM in connection herewith.

 

    25 

     

    

 

8.2.          Deliveries
of BTHE. At the Closing, BTHE shall deliver to CureDM and each of the CureDM Members:

 

 (a)       a
good standing or similar certificate of BTHE with respect to the status of BTHE in Delaware and in each other jurisdiction in which
it is qualified to do business, in each case, certified by the Secretary of State of the other relevant authority not more than
ten days prior to the Closing Date;

 

 (b)       a
copy of the certificate of incorporation of BTHE, certified by the Secretary of State of the State of Delaware not more than ten
days prior to the Closing Date;

 

 (c)       a
certificate, signed by the Secretary of BTHE, (i) certifying as true, accurate and complete the By-Laws of BTHE, and any amendments
thereto, (ii) certifying as true, accurate and complete the share register of BTHE as of the Closing Date, (iii) certifying as
true, accurate and complete copies of actions by written consent or resolutions duly adopted by the Board of Directors of BTHE
that authorize and approve the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated
by this Agreement, and (iv) certifying the incumbency, signature and authority of the officers of BTHE that are authorized to execute
this Agreement and any other documents, instruments or agreements to be executed and delivered in connection herewith; and

 

 (d)       evidence
that the CureDM designee has been duly appointed to the Board of Directors of BTHE.

 

SECTION 9

SURVIVAL OF REPRESENTATIONS AND WARRANTIES
OF BTHE

 

Notwithstanding any
right of CureDM and the CureDM Members to fully investigate the affairs of BTHE, CureDM and the CureDM Members shall have the right
to rely fully upon the representations, warranties, covenants and agreements of BTHE contained in this Agreement or in any document
delivered to CureDM and/or the CureDM Members by BTHE or any of its respective representatives, in connection with the transactions
contemplated by this Agreement. All representations and warranties of BTHE shall survive the Closing Date for a period ending on
one (1) year after the Closing Date unless otherwise specified in such representation or warranty. No claim may be asserted by
an Indemnified Party under Section 12 related to any such representations, warranties or covenants after such time period has expired;
provided however, that claims for any such Losses first asserted by timely delivery of a written notice within such period shall
continue to survive until such claim for indemnification is finally settled or satisfied in accordance with the terms hereof.

 

    26 

     

    

 

SECTION 10

SURVIVAL OF REPRESENTATIONS AND WARRANTIES
OF

CUREDM AND THE CUREDM MEMBERS

 

Notwithstanding any
right of BTHE to fully investigate the affairs of CureDM and the CureDM Members, BTHE has the right to rely fully upon the representations,
warranties, covenants and agreements of CureDM and the CureDM Members contained in this Agreement or in any document delivered
to BTHE by CureDM and/or the CureDM Members or any of their respective representatives, in connection with the transactions contemplated
by this Agreement. All such representations, warranties, covenants and agreements of CureDM and the CureDM Members, as applicable,
shall survive the Closing Date for a period ending one (1) year after the Closing Date. No claim may be asserted by an Indemnified
Party under Section 12 related to any such representations, warranties or covenants after such time period has expired; provided
however, that claims for any such Losses first asserted by timely delivery of a written notice within such period shall continue
to survive until such claim for indemnification is finally settled or satisfied in accordance with the terms hereof.

 

SECTION 11

INTENTIONALLY OMITTED

 

SECTION 12

INDEMNIFICATION

 

12.1         Obligation
of BTHE to Indemnify. Subject to the limitations on the survival of representations, warranties, covenants and agreements
contained in Section 9 and subject to the closing of the Equity Financing (or no mutual agreement to unwind the transaction per
Section 5.6 in the event of no Equity Financing by the Equity Financing Date), BTHE hereby agrees to indemnify, defend and hold
harmless each of the CureDM Members from and against any and all claims, losses, liabilities, damages, deficiencies, costs and
expenses (including interest, penalties and reasonable attorneys’ fees and disbursements) (each, a “Loss”
and collectively, the “Losses”) based upon, arising out of or otherwise due to any breach of, any material
representation, warranty, covenant or agreement of BTHE contained in this Agreement. BTHE may not settle or compromise any such
Loss without the prior written consent of the CureDM Members who, as of immediately prior to the Closing, held a majority in interest
of the CureDM Membership Interests, which consent may not be unreasonably withheld or delayed. Except to the extent the CureDM
Members are disproportionately affected by any such Loss, all amounts paid or payable by BTHE in connection with any indemnification
claim made pursuant to this Section 12.1 shall be allocated ratably among the CureDM Members in accordance with their relative
holdings of CureDM Membership Interests as set forth on Schedule A.

 

12.2         Obligation
of the CureDM Members to Indemnify Related to Section 4 Representations and Warranties. Subject to the limitations on the
survival of representations, warranties, covenants and agreements contained in Section 10 and subject to the closing of the Equity
Financing (or no mutual agreement to unwind the transaction per Section 5.6 in the event of no Equity Financing by the Equity Financing
Date), each CureDM Member agrees, severally but not jointly, to indemnify, defend and hold harmless BTHE from and against any Loss
based upon, arising out of, or otherwise due to any breach of any material representation, warranty, covenant or agreement made
by such CureDM Member and contained in Section 4 of this Agreement. The CureDM Members may not settle or compromise any such Loss
without the prior written consent of BTHE, which consent may not be unreasonably withheld or delayed; provided that each
CureDM Member’s aggregate liability under this Section 12.2 shall in no event exceed 50% of the lesser of: (i) the value
of the Closing BTHE Shares received by such CureDM Member as of the Closing Date and (ii) the value of such Closing BTHE Shares
as of the date of the Indemnification Notice (defined below) or if such Closing BTHE Shares have been disposed of or sold by such
CureDM Member prior to the date of the Indemnification Notice, the consideration received in the sale of such Closing BTHE Shares.
In the event the BTHE Shares are no longer publicly traded as of the date of the Indemnification Notice, such CureDM Member shall
have the option to tender 50% of the Closing BTHE Shares received by such CureDM Member as of the Closing Date in satisfaction
of the indemnification obligation hereunder.

 

    27 

     

    

 

12.3         Obligation
of CureDM, Inc. and Loraine V. Upham to Indemnify Related to Section 2 Representations and Warranties. Subject to the limitations
on the survival of representations, warranties, covenants and agreements contained in Section 10 and subject to the closing of
the Equity Financing (or no mutual agreement to unwind the transaction per Section 5.6 in the event of no Equity Financing by the
Equity Financing Date), CureDM, Inc. and Loraine V. Upham each agree, severally but not jointly on a pro rata basis based upon
such Member’s total membership interest in CureDM as of the Closing Date (and in addition to the obligations in Section 12.2
above), to indemnify, defend and hold harmless BTHE from and against any Loss based upon, arising out of, or otherwise due to any
breach of any material representation, warranty, covenant or agreement made by such CureDM Member and contained in Section 2 of
this Agreement. CureDM, Inc. and Loraine V. Upham may not settle or compromise any such Loss without the prior written consent
of BTHE, which consent may not be unreasonably withheld or delayed; provided that the respective aggregate liability of
either CureDM, Inc. and Loraine V. Upham under this Section 12.3 shall in no event exceed 10% of the lesser of: (i) the value of
the Closing BTHE Shares received by CureDM, Inc. or Loraine V. Upham, as applicable, as of the Closing Date and (ii) the value
of such Closing BTHE Shares as of the date of the Indemnification Notice (defined below) or if such Closing BTHE Shares have been
disposed of or sold by CureDM, Inc. or Loraine V. Upham, as applicable, prior to the date of the Indemnification Notice, the consideration
received in the sale of such Closing BTHE Shares. In the event the BTHE Shares are no longer publicly traded as of the date of
the Indemnification Notice, CureDM, Inc. and Loraine V. Upham, as applicable, shall have the option to tender 10% of their respective
Closing BTHE Shares received as of the Closing Date in satisfaction of the indemnification obligation hereunder.

 

12.4         Deductible.
An Indemnifying Party shall not be required to indemnify the Indemnified Party until the aggregate amount of all Losses for which
the Indemnifying Party would, but for this Section 12.4 be liable under Sections 12.1, 12.2 or 12.3, as applicable,
exceeds on a cumulative basis an amount equal to $50,000 (the “Deductible”), in which case, the Indemnifying
Party shall become liable for Losses in excess of the Deductible (but shall not be liable for losses below or up to the amount
of the Deductible).

 

12.5         Defense
of Third-Party Claims. In the event of the assertion or commencement of any claim with respect to which a party may be entitled
to indemnification, compensation or reimbursement pursuant to this Section 12 (an “Indemnified Party”),
the Indemnified Party shall have the right, at its election, to proceed with the defense of such claim or proceeding on its own
with counsel. Except as provided in Section 12.1, 12.2 or 12.3, the Indemnified Party shall have the right to settle, adjust or
compromise such claim or proceeding, and shall provide the party required to provide such indemnification hereunder (the “Indemnifying
Party”) with prompt notice after it becomes aware of the commencement of any such claim or proceeding (the “Indemnification
Notice”); provided, however, that any failure on the part of the Indemnified Party to so notify the Indemnifying
Party shall not limit any of the obligations of the Indemnified Party, or any of the rights of the Indemnified Party, under this
Section 12 (except to the extent such failure materially prejudices the defense of such claim or proceeding). If the Indemnified
Party does not elect to proceed with the defense of any such claim or proceeding, the Indemnifying Party may proceed with the defense
with counsel reasonably satisfactory to the Indemnified Party; provided, however, that the Indemnifying Party may not settle
or compromise any such claim or proceeding without the prior written consent of the Indemnified Party (which consent may not be
unreasonably withheld or delayed).

 

    28 

     

    

 

SECTION 13

MISCELLANEOUS

 

13.1         Waivers.
Any term or provision of this Agreement may be waived, or the time for its performance may be extended, by the party entitled to
the benefit thereof. Any such waiver shall be validly and sufficiently authorized for the purposes of this Agreement if, as to
any party, it is in writing signed by an authorized representative of such party. The failure or delay of any party to enforce
at any time any provision of this Agreement shall not be construed to be a waiver of such provision, nor in any way to affect the
validity of this Agreement or any part hereof or the right of any party thereafter to enforce each and every such provision. The
waiver of a breach of this Agreement shall in no event constitute waiver as to any future breach whether similar or dissimilar
in nature or as to the exercise of any further right under this Agreement.

 

13.2         Binding
Agreement; Assignment. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their
respective heirs, legal representatives, successors and permitted assigns. This Agreement is not assignable except by operation
of law; provided, following the closing of the Equity Financing, that any CureDM Member may assign, in its sole discretion,
any or all of its rights, interests and obligations under this Agreement to any of its affiliates or to any transferee of the BTHE
Shares following the Closing Date. No such assignment, delegation or other transfer shall relieve the assignor of any of its obligations
or liabilities hereunder.

 

13.3         Notices.
Any notice or statement given under this Agreement shall be in writing and shall be deemed given or delivered (i) when delivered
personally, (ii) when delivered by electronic mail (so long as notification of a failure to deliver such electronic mail is not
received by the sending party), (iii) if transmitted by facsimile when confirmation of transmission is received by the sending
party, (iv) if sent by registered or certified mail, postage prepaid, return receipt requested, on the third business day after
mailing or (v) if sent by reputable overnight courier when received, to the other party(ies) at the addresses indicated above or
on Schedule A hereto or at such other address or number as may be furnished in writing in accordance with this paragraph.
Any party hereto may, from time to time, change its address, facsimile number, e-mail address or other information for the purpose
of notices to that party by giving notice specifying such change to the other parties hereto.

 

    29 

     

    

 

13.4         Governing
Law; Venue. This Agreement shall be governed and construed in accordance with the laws of the State of Delaware, without
regard to the conflicts of law provisions thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state
and federal courts sitting in New York County, State of New York, for the adjudication of any dispute hereunder or in connection
herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert
in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such
suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action
or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that
such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HERETO IRREVOCABLY WAIVES ANY RIGHT
TO TRIAL BY JURY.

 

13.5         Entire
Agreement. This Agreement, including the Schedules hereto and any collateral agreements executed in connection herewith,
contains the entire agreement among the parties with respect to the transaction and issuance of the BTHE Shares and related transactions,
and supersedes all prior agreements, written or oral, with respect thereto. This Agreement may only be amended by a written instrument
signed by each of the parties hereto.

 

13.6         Headings.
The headings in this Agreement are for reference purposes only and shall not in any way affect the meaning or interpretation of
this Agreement.

 

13.7         Severability
of Provisions. The invalidity or unenforceability of any term, phrase, clause, paragraph, restriction, covenant, agreement
or other provision of this Agreement shall in no way affect the validity or enforcement of any other provision or any part thereof.

 

13.8         Counterparts;
Facsimile. This Agreement may be executed in any number of counterparts, each of which, when so executed, shall constitute
an original copy hereof, but all of which together shall consider but one and the same document. This Agreement may be executed
and delivered by facsimile transmission or pdf via email and when so executed and delivered shall have the same effect as if the
receiving party had received an original counterpart of this Agreement.

 

13.9         No
Third Party Beneficiaries. Nothing in this Agreement, express or implied, is intended or shall be construed to confer upon
any third person, other than the parties and their respective successors and assigns permitted by Section 13.2, any right, remedy
or claim under or by reason of this Agreement.

 

    30 

     

    

 

IN WITNESS WHEREOF,
the parties have executed this Agreement on the date first above written.

 

	 	BOSTON THERAPEUTICS,
INC.
	 	 
	 	By:	 
	 	Name: Carl W. Rausch
Title: CEO
	 	 
	 	CUREDM GROUP
HOLDINGS, LLC
	 	 
	 	By:	 
	 	Name: Loraine V. Upham
Title: President and CEO

 

[Signature Page to Contribution Agreement]

 

     

     

    

 

IN WITNESS WHEREOF, the
parties have executed this Agreement on the date first above written.

 

	 	CUREDM
MEMBERS:
	 	 	 
	 	Entities:
	 	 	 

 

	 	By:	 

	 	Name:	 

	 	Title: 	 

 

	 	Individuals:
	 	 	 
	 	Print
Name:  

 

[Signature Page to Contribution Agreement]

 

     

     

    

 

Schedule A

 

     

     

    

 

Schedule B

 

     

     

    

 

CureDM Disclosure Schedule

 

Schedule 2.1 - Board of Directors; Committees

 

Schedule 2.7 - CureDM Intellectual Property

 

Schedule 2.13(b) - Leased Real Property

 

2.14(b) - Licensed
Personal Property Assets

 

2.14(c) – Owned Personal Property Assets

 

Schedule 2.16 - Financial Statements

 

Schedule 2.24(d) - Products/Product Candidates

 

Schedule 4.4 – List of Non-Accredited CureDM Members

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}]]